H0777 • 2026

UNIFORM CONTROLLED SUBSTANCES – Amends existing law to revise provisions regarding controlled substances.

Enacted

This bill passed the Legislature and reached final enactment based on the latest official action.

Sponsor: HEALTH AND WELFARE COMMITTEE
Last action: 2026-03-23
Official status: LAW
Effective date: 2026-07-01

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

UNIFORM CONTROLLED SUBSTANCES – Amends existing law to revise provisions regarding controlled substances.

What This Bill Does

UNIFORM CONTROLLED SUBSTANCES – Amends existing law to revise provisions regarding controlled substances.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-03-23 Idaho State Legislature
Reported Signed by Governor on March 20, 2026 Session Law Chapter 90 Effective: 07/01/2026
2026-03-20 Idaho State Legislature
Delivered to Governor at 4:32 p.m. on March 19, 2026
2026-03-19 Idaho State Legislature
Received from the House enrolled/signed by Speaker
2026-03-19 Idaho State Legislature
Signed by President; returned to House
2026-03-19 Idaho State Legislature
Returned Signed by the President; Ordered Transmitted to Governor
2026-03-18 Idaho State Legislature
Returned from Senate Passed; to JRA for Enrolling
2026-03-18 Idaho State Legislature
Reported Enrolled; Signed by Speaker; Transmitted to Senate
2026-03-17 Idaho State Legislature
Retained on calendar
2026-03-17 Idaho State Legislature
Read third time in full – PASSED - 34-0-1 AYES – Adams, Anthon, Bernt, Bjerke(Bjerke), Blaylock, Burtenshaw, Carlson, Cook, Den Hartog, Foreman, Galloway, Grow, Guthrie, Harris, Hart, Kohl, Lakey, Lenney, Lent, Nichols, Okuniewicz, Ricks, Ruchti, Semmelroth, Shippy, Taylor, Toews, VanOrden, Ward-Engelking, Wintrow, Woller(Rabe), Woodward, Zito, Zuiderveld NAYS – None Absent and excused – Keyser Floor Sponsor - Shippy Title apvd - to House
2026-03-16 Idaho State Legislature
Retained on calendar
2026-03-10 Idaho State Legislature
Read second time; filed for Third Reading
2026-03-09 Idaho State Legislature
Reported out of Committee with Do Pass Recommendation; Filed for second reading
2026-03-03 Idaho State Legislature
Received from the House passed; filed for first reading
2026-03-03 Idaho State Legislature
Introduced, read first time; referred to: Health & Welfare
2026-03-02 Idaho State Legislature
Read Third Time in Full – PASSED - 65-1-4 AYES – Alfieri, Barbieri, Beiswenger, Berch, Bingham, Boyle, Bruce, Burgoyne, Cannon, Cayler, Cheatum, Church, Cornilles, Crane(12), Crane(13), Dygert, Egbert, Ehardt, Ehlers, Erickson, Fuhriman, Gannon, Garner, Green, Hall(Stone), Handy, Harris, Haws(Woller), Healey, Hill(Brown), Holtzclaw, Hostetler, Leavitt, Manwaring, Marmon, Mathias, McCann, Mendive, Miller, Mitchell, Monks, Nelsen, Palmer, Petzke, Pickett, Pohanka, Price, Rasor, Raybould, Raymond, Redman, Sauter, Scott, Shepherd, Shirts, Skaug, Tanner(13), Tanner(14), Thompson, Vander Woude, Veile, Weber, Wheeler, Wisniewski, Mr. Speaker NAYS – Hawkins Absent – Furniss, Galaviz, Mickelsen, Rubel Floor Sponsor - Erickson Title apvd - to Senate
2026-02-27 Idaho State Legislature
Read second time; Filed for Third Reading
2026-02-26 Idaho State Legislature
Reported Printed; Filed for Second Reading
2026-02-25 Idaho State Legislature
Introduced, read first time, referred to JRA for Printing

Official Summary Text

UNIFORM CONTROLLED SUBSTANCES – Amends existing law to revise provisions regarding controlled substances.

Current Bill Text

Read the full stored bill text

LEGISLATURE
OF
THE
STATE
OF
IDAHO
Sixty-eighth
Legislature
Second
Regular
Session
-
2026
IN
THE
HOUSE
OF
REPRESENTATIVES
HOUSE
BILL
NO.
777
BY
HEALTH
AND
WELFARE
COMMITTEE
AN
ACT
1
RELATING
TO
UNIFORM
CONTROLLED
SUBSTANCES;
AMENDING
SECTION
37
-
2705,
IDAHO
2
CODE,
TO
REVISE
PROVISIONS
REGARDING
SCHEDULE
I
CONTROLLED
SUBSTANCES
3
AND
TO
MAKE
TECHNICAL
CORRECTIONS;
AMENDING
SECTION
37
-
2707,
IDAHO
4
CODE,
TO
REVISE
PROVISIONS
REGARDING
SCHEDULE
II
CONTROLLED
SUBSTANCES
5
AND
TO
MAKE
TECHNICAL
CORRECTIONS;
AMENDING
SECTION
37
-
2709,
IDAHO
6
CODE,
TO
REVISE
PROVISIONS
REGARDING
SCHEDULE
III
CONTROLLED
SUB
-
7
STANCES
AND
TO
MAKE
TECHNICAL
CORRECTIONS;
AMENDING
SECTION
37
-
2711,
8
IDAHO
CODE,
TO
REVISE
PROVISIONS
REGARDING
SCHEDULE
IV
CONTROLLED
SUB
-
9
STANCES
AND
TO
MAKE
TECHNICAL
CORRECTIONS;
AMENDING
SECTION
37
-
2713,
10
IDAHO
CODE,
TO
REVISE
PROVISIONS
REGARDING
SCHEDULE
V
CONTROLLED
SUB
-
1
1
STANCES;
AMENDING
SECTION
37
-
2716,
IDAHO
CODE,
TO
REVISE
PROVISIONS
12
REGARDING
REGISTRATION
REQUIREMENTS;
AMENDING
SECTION
37
-
2717,
IDAHO
13
CODE,
TO
REVISE
A
PROVISION
REGARDING
REGISTRATION;
AMENDING
SEC
-
14
TION
37
-
2718,
IDAHO
CODE,
TO
REVISE
PROVISIONS
REGARDING
DISCIPLINE;
15
AMENDING
SECTION
37
-
2719,
IDAHO
CODE,
TO
REVISE
PROVISIONS
REGARD
-
16
ING
ORDERS
TO
SHOW
CAUSE;
AMENDING
SECTION
37
-
2720,
IDAHO
CODE,
TO
17
REVISE
A
PROVISION
REGARDING
RECORDS,
DRUG
STORAGE,
AND
INVENTORY;
18
AMENDING
SECTION
37
-
2722,
IDAHO
CODE,
TO
REVISE
PROVISIONS
REGARDING
19
ISSUING,
DISTRIBUTING,
AND
DISPENSING
OF
CONTROLLED
SUBSTANCES
AND
TO
20
MAKE
TECHNICAL
CORRECTIONS;
AMENDING
SECTION
37
-
2726,
IDAHO
CODE,
TO
21
REVISE
PROVISIONS
REGARDING
THE
CONTROLLED
SUBSTANCES
PRESCRIPTIONS
22
DATABASE;
AMENDING
SECTION
37
-
2731,
IDAHO
CODE,
TO
REVISE
A
PROVISION
23
REGARDING
INFORMATION
REQUIRED
ON
LABELS;
AND
DECLARING
AN
EMERGENCY
24
AND
PROVIDING
AN
EFFECTIVE
DATE.
25
Be
It
Enacted
by
the
Legislature
of
the
State
of
Idaho:
26
SECTION
1.
That
Section
37
-
2705,
Idaho
Code,
be,
and
the
same
is
hereby
27
amended
to
read
as
follows:
28
37
-
2705.
SCHEDULE
I.
(a)
The
controlled
substances
listed
in
this
sec
-
29
tion
are
included
in
schedule
I.
30
(b)
Any
of
the
following
opiates,
including
their
isomers,
esters,
31
ethers,
salts,
and
salts
of
isomers,
esters,
and
ethers,
unless
specifically
32
excepted,
whenever
the
existence
of
these
isomers,
esters,
ethers
and
salts
33
is
possible
within
the
specific
chemical
designation:
34
(1)
Acetyl
-
alpha
-
methylfentanyl
(N
-
[1
-
(1
-
methyl
-
2
-
phenethyl)
-
4
-
pip
-
35
eridinyl]
-
N
-
phenylacetamide)
;
36
(2)
Acetylmethadol;
37
(3)
Acetyl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
phenylac
-
38
etamide)
;
39
(4)
Acryl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
phenylacry
-
40
lamide)
;
41
(5)
Allylprodine;
42

2
(6)
Alphacetylmethadol
(except
levo
-
alphacetylmethadol
also
known
as
1
levo
-
alpha
-
acetylmethadol,
levomethadyl
acetate
or
LAAM);
2
(7)
Alphameprodine;
3
(8)
Alphamethadol;
4
(9)
Alpha'
-
methyl
butyryl
fentanyl
(2
-
methyl
-
N
-
(1
-
phenethylpiperidi
-
5
n
-
4
-
yl)
-
N
-
phenylbutanamide)
;
6
(10)
Alpha
-
methylfentanyl;
7
(11)
Alpha
-
methylthiofentanyl
(N
-
[1
-
methyl
-
2
-
(2
-
thienyl)ethyl
-
4
-
8
piperidinyl]
-
N
-
phenylpropanamide)
;
9
(12)
Benzethidine;
10
(13)
Betacetylmethadol;
1
1
(14)
Beta
-
hydroxyfentanyl
(N
-
[1
-
(2
-
hydroxy
-
2
-
phenethyl)
-
4
-
piperid
-
12
inyl]
-
N
-
phenylpropanamide)
;
13
(15)
Beta
-
hydroxythiofentanyl;
14
(16)
Beta
-
hydroxy
-
3
-
methylfentanyl
(N
-
(1
-
(2
-
hydroxy
-
2
-
phenethyl)
-
3
-
15
methyl
-
4
-
piperidinyl)
-
N
-
phenylpropanamide)
;
16
(17)
Betameprodine;
17
(18)
Betamethadol;
18
(19)
Beta
-
methyl
fentanyl;
19
(20)
Beta
-
methylacetyl
fentanyl;
20
(20)
(21)
Beta'
-
phenyl
fentanyl;
21
(21)
(22)
Betaprodine;
22
(22)
(23)
Brorphine
(1
-
(1
-
(1
-
(4
-
Bromophenyl)ethyl)piperidin
-
4
-
yl)
-
23
1,3
-
dihydro
-
2H
-
benzo[D]imidazol
-
2
-
one)
;
24
(23)
(24)
Butonitazene
(2
-
(2
-
(4
-
butoxybenzyl)
-
5
-
nitro
-
1hbenzimida
-
25
zol
-
1
-
yl)
-
N,N
-
diethylethan
-
1
-
amine)
;
26
(24)
(25)
Clonitazene;
27
(25)
(26)
Crotonyl
fentanyl
((E)
-
N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
28
phenylbut
-
2
-
enamide)
;
29
(26)
(27)
Cyclopentyl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
30
phenylcyclopentanecarboxamide)
;
31
(27)
(28)
Cyclopropyl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
32
phenylcyclopropanecarboxamide)
;
33
(28)
(29)
Dextromoramide;
34
(29)
(30)
Diampromide;
35
(30)
(31)
Diethylthiambutene;
36
(31)
(32)
Difenoxin;
37
(32)
(33)
Dimenoxadol;
38
(33)
(34)
Dimepheptanol;
39
(34)
(35)
2',5'
-
Dimethoxyfentanyl
(N
-
(1
-
(2,5
-
dimethoxyphenethyl)pip
-
40
eridin
-
4
-
yl)
-
N
-
phenylpropionamide)
;
41
(35)
(36)
Dimethylthiambutene;
42
(36)
(37)
Dioxaphetyl
butyrate;
43
(37)
(38)
Dipipanone;
44
(38)
(39)
Ethylmethylthiambutene;
45
(39)
(40)
Etodesnitazene
;
(
Etazene
)
(2
-
(2
-
(4
-
ethoxybenzyl)
-
1hbenzim
-
46
idazol
-
1
-
yl)
-
N,N
-
diethylethan
-
1
-
amine)
;
47
(40)
(41)
Etonitazene;
48
(41)
(42)
Etoxeridine;
49

3
(42)
(43)
Fentanyl
-
related
substances.
"Fentanyl
-
related
substances"
1
means
any
substance
not
otherwise
listed
and
for
which
no
exemption
or
2
approval
is
in
effect
under
section
505
of
the
federal
food,
drug,
and
3
cosmetic
act,
21
U.S.C.
355,
and
that
is
structurally
related
to
fen
-
4
tanyl
by
one
(1)
or
more
of
the
following
modifications:
5
i.
Replacement
of
the
phenyl
portion
of
the
phenethyl
group
by
any
6
monocycle,
whether
or
not
further
substituted
in
or
on
the
monocy
-
7
cle;
8
ii.
Substitution
in
or
on
the
phenethyl
group
with
alkyl,
alkenyl,
9
alkoxyl,
hydroxyl,
halo,
haloalkyl,
amino,
or
nitro
groups;
10
iii.
Substitution
in
or
on
the
piperidine
ring
with
alkyl,
1
1
alkenyl,
alkoxyl,
ester,
ether,
hydroxyl,
halo,
haloalkyl,
amino,
12
or
nitro
groups;
13
iv.
Replacement
Substitution
in
or
on
the
aniline
ring
or
replace
-
14
ment
of
the
aniline
ring
with
any
aromatic
monocycle,
whether
or
15
not
further
substituted
in
or
on
the
aromatic
monocycle;
and/or
16
v.
Replacement
of
the
N
-
propionyl
group
by
another
acyl
group;
17
(43)
(44)
Fentanyl
carabamate;
18
(44)
(45)
Flunitazene
(N,N
-
diethyl
-
2
-
(2
-
(4
-
fluorobenzyl)
-
5
-
nitro
-
1h
-
19
benzimidazol
-
1
-
yl)ethan
-
1
-
amine)
;
20
(45)
(46)
4
-
Fluoroisobutyryl
fentanyl
(N
-
(4
-
fluorophenyl)
-
N
-
(1
-
21
phenethylpiperidin
-
4
-
yl)isobutyramide)
;
22
(46)
(47)
2'
-
fluoro
ortho
-
fluorofentanyl;
23
(47)
(48)
Furanyl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
phenyl
-
24
furan
-
2
-
carboxamide)
;
25
(48)
(49)
3
-
Furanyl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
26
phenylfuran
-
3
-
carboxamide)
;
27
(49)
(50)
Furethidine;
28
(50)
(51)
Hydroxypethidine;
29
(51)
(52)
Isobutyryl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
30
phenylisobutyramide)
;
31
(52)
(53)
Isovalery
fentanyl
(3
-
methyl
-
N
-
(1
-
phenethylpiperidin
-
4
-
32
yl)
-
N
-
phenylbutanimide)
;
33
(53)
(54)
Isotonitazene
(N,N
-
diethyl
-
2
-
(2
-
(4isopropoxybenzyl)
-
5
-
ni
-
34
tro
-
1h
-
benzimidazol
-
1
-
yl)ethan
-
1
-
amine)
;
35
(54)
(55)
Ketobemidone;
36
(55)
(56)
Levomoramide;
37
(56)
(57)
Levophenacylmorphan;
38
(57)
(58)
Meta
-
fluorofentanyl
(N
-
(3
-
fluorophenyl)
-
N
-
(1
-
39
phenethylpiperidin
-
4
-
yl)isobutyramide)
;
40
(59)
Meta
-
fluorofuranyl
fentanyl;
41
(58)
(60)
Meta
-
fluoroisobutyryl
fentanyl
(N
-
(3
-
fluorophenyl)
-
N
-
(1
-
42
phenethylpiperidin
-
4
-
yl)isobutyramide)
;
43
(59)
(61)
Methoxyacetyl
fentanyl
(2
-
methoxy
-
N
-
(1
-
phenethylpiperidin
-
44
4
-
yl)
-
N
-
phenylacetamide)
;
45
(60)
(62)
2
-
Methyl
AP
-
237
(1
-
(2
-
methyl
-
4
-
(3
-
phenylprop
-
2
-
en
-
1
-
46
yl)piperazin
-
1
-
yl)butan
-
1
-
one)
;
47
(61)
(63)
4'
-
methyl
acetyl
fentanyl;
48
(62)
(64)
3
-
Methylfentanyl;
49

4
(63)
(65)
3
-
methylthiofentanyl
(N
-
[(3
-
methyl
-
1
-
(2
-
thienyl)ethyl
-
4
-
1
piperidinyl]
-
N
-
phenylpropanamide)
(and
optical
and
geometric
isomers
2
of
3
-
methylthiofentanyl)
;
3
(64)
(66)
Metodesnitazene
(N,N
-
diethyl
-
2
-
(2
-
(4
-
methoxybenzyl)
-
1h
-
4
benzimidazol
-
1
-
yl)ethan
-
1
-
amine)
;
5
(65)
(67)
Metonitazene
(N,N
-
diethyl
-
2
-
(2
-
(4
-
methoxybenzyl)
-
5
-
ni
-
6
tro
-
1hbenzimidazol
-
1
-
yl)ethan
-
1
-
amine)
;
7
(66)
(68)
Morpheridine;
8
(67)
(69)
MPPP
(1
-
methyl
-
4
-
phenyl
-
4
-
propionoxypiperidine);
9
(68)
(70)
MT
-
45
(1
-
cyclohexyl
-
4
-
(1,2
-
diphenylethyl)piperazine);
10
(69)
(71)
N
-
(4
-
chlorophenyl)
-
N
-
(1
-
phenethylpiperdin
-
4
-
yl)Isobutyra
-
1
1
mide
(p
P
ara
-
chloroisobutyrl
fentanyl
)
;
12
(70)
(72)
Noracymethadol;
13
(71)
(73)
Norlevorphanol;
14
(72)
(74)
Normethadone;
15
(73)
(75)
Norpipanone;
16
(76)
N
-
desethyl
isotonitazene;
17
(77)
N
-
piperidinyl
etonitazene;
18
(74)
(78)
N
-
pyrrolidino
etonitazene
(2
-
(4
-
ethoxybenzyl)
-
5
-
ni
-
19
tro
-
1
-
(2
-
(pyrrolidin
-
1
-
yl)ethyl)1hbenzimidazole)
;
20
(75)
(79)
Ocfentanil
(N
-
(2
-
fluorophenyl)
-
2
-
methoxy
-
N
-
(1
-
phenethyl
-
21
piperidin
-
4
-
yl)acetamide)
;
22
(80)
Ortho
-
chlorofentanyl;
23
(76)
(81)
Ortho
-
fluoroacryl
fentanyl;
24
(77)
(82)
Ortho
-
fluorobutyrl
fentanyl;
25
(78)
(83)
Ortho
-
fluorofentanyl;
26
(79)
(84)
Ortho
-
fluorofuranyl
fentanyl
(N
-
(2
-
fluorophenyl)
-
N
-
(1
-
27
phenethylpiperidin
-
4
-
yl)furan
-
2
-
carboxamide)
;
28
(80)
(85)
Ortho
-
fluoroisobutyryl
fentanyl;
29
(81)
(86)
Ortho
-
methyl
acetylfentanyl;
30
(87)
Ortho
-
methylcyclopropylfentanyl;
31
(82)
(88)
Ortho
-
methyl
methoxyacetyl
fentanyl;
32
(89)
Para
-
chlorofentanyl;
33
(83)
(90)
Para
-
chloroisobutyryl
fentanyl
(N
-
(4
-
chlorophenyl)
-
N
-
(1
-
34
phenethylpiperidin
-
4
-
yl)
isobutyramide)
;
35
(84)
(91)
Para
-
fluorobutyryl
fentanyl
(N
-
(4
-
fluorophenyl)
-
N
-
(1
-
36
phenethylpiperidin
-
4
-
yl)
butyramide)
;
37
(85)
(92)
Para
-
fluorofentanyl
(N
-
(4
-
fluorophenyl)
-
N
-
[1
-
(2
-
phen
-
38
ethyl)
-
4
-
piperidinyl]
propanamide)
;
39
(86)
(93)
Para
-
fluoro
furanyl
fentanyl;
40
(94)
Para
-
fluoro
valeryl
fentanyl;
41
(87)
(95)
Para
-
methoxybutyryl
fentanyl
(N
-
(4
-
methoxyphenyl)
-
N
-
(1
-
42
phenethylpiperidin
-
4
-
yl)
butyramide)
;
43
(88)
(96)
Para
-
methoxyfuranyl
fentanyl
(N
-
(4
-
methoxyphenyl)
-
N
-
(1
-
44
phenethylpiperidin
-
4
-
yl)furan
-
2
-
carboxamide)
;
45
(89)
(97)
Para
-
methylcyclopropyl
fentanyl
(N
-
(4
-
methylphenyl)
-
N
-
(1
-
46
phenylpiperidin
-
4
-
yl)cyclopropanecarboxamide)
;
47
(90)
(98)
Para
-
methylfentanyl;
48
(91)
(99)
PEPAP
(1
-
(
-
2
-
phenethyl)
-
4
-
phenyl
-
4
-
acetoxypiperidine);
49
(92)
(100)
Phenadoxone;
50

5
(93)
(101)
Phenampromide;
1
(94)
(102)
Phenomorphan;
2
(95)
(103)
Phenoperidine;
3
(96)
(104)
Phenyl
fentanyl;
4
(97)
(105)
Piritramide;
5
(98)
(106)
Proheptazine;
6
(99)
(107)
Properidine;
7
(100)
(108)
Propiram;
8
(101)
(109)
Protonitazene
(N,N
-
diethyl
-
2
-
(5
-
nitro
-
2
-
(4
-
propoxyben
-
9
zyl)
-
1h
-
benzimidazol
-
1
-
yl)ethan
-
1
-
amine)
;
10
(102)
(110)
Racemoramide;
1
1
(103)
(111)
Tetrahydrofuranyl
fentanyl
(N
-
(1
-
phenethylpiperi
-
12
dine
-
4
-
yl)
-
N
-
phenyltetrahydrofuran
-
2
-
carboxamide)
;
13
(112)
Tetrahydrothiofuranyl
fentanyl;
14
(104)
(113)
Thiofentanyl
(N
-
phenyl
-
N
-
[1
-
(2
-
thienyl)ethyl
-
4
-
piper
-
15
idinyl]
-
propanamide)
;
16
(105)
(114)
Tilidine;
17
(106)
(115)
Trimeperidine;
18
(107)
(116)
u
-
47700
(3,4
-
Dichloro
-
N
-
[2
-
(dimethylamino)cyclohexyl]
-
N
-
19
methylbenzamide);
20
(108)
(117)
Valeryl
fentanyl
(N
-
(1
-
phenethylpiperidin
-
4
-
yl)
-
N
-
21
phenylpentanamide)
;
22
(109)
(118)
Zipeprol
(1
-
methoxy
-
3
-
[4
-
(2
-
methoxy
-
2
-
phenylethyl)piper
-
23
azin
-
1
-
yl]
-
1
-
phenylpropan
-
2
-
ol)
.
24
(c)
Any
of
the
following
opium
derivatives,
their
salts,
isomers
and
25
salts
of
isomers,
unless
specifically
excepted,
whenever
the
existence
of
26
these
salts,
isomers
and
salts
of
isomers
is
possible
within
the
specific
27
chemical
designation:
28
(1)
Acetorphine;
29
(2)
Acetyldihydrocodeine;
30
(3)
Benzylmorphine;
31
(4)
Codeine
methylbromide;
32
(5)
Codeine
-
N
-
Oxide;
33
(6)
Cyprenorphine;
34
(7)
Desomorphine;
35
(8)
Dihydromorphine;
36
(9)
Drotebanol;
37
(10)
Etorphine
(except
hydrochloride
salt);
38
(11)
Heroin;
39
(12)
Hydromorphinol;
40
(13)
Methyldesorphine;
41
(14)
Methyldihydromorphine;
42
(15)
Morphine
methylbromide;
43
(16)
Morphine
methylsulfonate;
44
(17)
Morphine
-
N
-
Oxide;
45
(18)
Myrophine;
46
(19)
Nicocodeine;
47
(20)
Nicomorphine;
48
(21)
Normorphine;
49
(22)
Pholcodine;
50

6
(23)
Thebacon.
1
(d)
Hallucinogenic
substances.
Any
material,
compound,
mixture
or
2
preparation
that
contains
any
quantity
of
the
following
hallucinogenic
3
substances,
their
salts,
isomers
and
salts
of
isomers,
unless
specifically
4
excepted,
whenever
the
existence
of
these
salts,
isomers,
and
salts
of
iso
-
5
mers
is
possible
within
the
specific
chemical
designation
(for
purposes
of
6
this
subsection
only,
the
term
"isomer"
includes
the
optical,
position
and
7
geometric
isomers):
8
(1)
Dimethoxyphenethylamine,
or
any
compound
not
specifically
9
excepted
or
listed
in
another
schedule
that
can
be
formed
from
10
dimethoxyphenethylamine
by
replacement
of
one
(1)
or
more
hydrogen
1
1
atoms
with
another
atom(s),
functional
group(s)
or
substructure(s)
12
including,
but
not
limited
to,
compounds
such
as
DOB,
DOC,
2C
-
B,
13
25B
-
NBOMe;
14
(2)
Methoxyamphetamine
or
any
compound
not
specifically
excepted
or
15
listed
in
another
schedule
that
can
be
formed
from
methoxyamphetamine
16
by
replacement
of
one
(1)
or
more
hydrogen
atoms
with
another
atom(s),
17
functional
group(s)
or
substructure(s)
including,
but
not
limited
to,
18
compounds
such
as
PMA
and
DOM;
19
(3)
5
-
methoxy
-
3,4
-
methylenedioxy
-
amphetamine;
20
(4)
5
-
methoxy
-
N,N
-
diisopropyltryptamine
(5
-
MeO
-
DIPT)
;
21
(5)
Amphetamine
or
methamphetamine
with
a
halogen
substitution
on
the
22
benzyl
ring,
including
compounds
such
as
fluorinated
amphetamine
and
23
fluorinated
methamphetamine;
24
(6)
3,4
-
methylenedioxy
amphetamine
(MDA)
;
25
(7)
3,4
-
methylenedioxymethamphetamine
(MDMA);
26
(8)
3,4
-
methylenedioxy
-
N
-
ethylamphetamine
(
also
known
as
N
-
et
-
27
hyl
-
alpha
-
methyl
-
3,4
(methylenedioxy)
phenethylamine,
and
N
-
et
-
28
hyl
MDA,
MDE,
MDEA);
29
(9)
N
-
hydroxy
-
3,4
-
methylenedioxyamphetamine
(
also
known
as
N
-
hyd
-
30
roxy
-
alpha
-
methyl
-
3,4(methylenedioxy)
phenethylamine,
and
N
-
hyd
-
31
roxy
MDA);
32
(10)
3,4,5
-
trimethoxy
amphetamine;
33
(11)
5
-
methoxy
-
N,N
-
dimethyltryptamine
(
also
known
as
5
-
methoxy
-
3
-
2[2
-
34
(dimethylamino)ethyl]indole
and
5
-
MeO
-
DMT);
35
(12)
Alpha
-
ethyltryptamine
(
some
other
names:
etryptamine,
3
-
(2
-
am
-
36
inobutyl)
indole
AET
);
37
(13)
Alpha
-
methyltryptamine
(AMT)
;
38
(14)
Bufotenine;
39
(15)
Diethyltryptamine
(DET);
40
(16)
Dimethyltryptamine
(DMT);
41
(17)
Ibogaine;
42
(18)
Lysergic
acid
diethylamide
(LSD)
;
43
(19)
Marihuana
(marijuana)
;
44
(20)
Mescaline;
45
(21)
Methoxetamine;
46
(22)
Parahexyl;
47
(23)
Peyote;
48
(24)
N
-
ethyl
-
3
-
piperidyl
benzilate;
49
(25)
N
-
methyl
-
3
-
piperidyl
benzilate;
50

7
(26)
Para
-
methoxymethamphetamine
(PMMA)
,
1
-
(4
-
methoxyphenyl)
-
N
-
1
methylpropan
-
2
-
amine
;
2
(27)
Psilocybin;
3
(28)
Psilocyn;
4
(29)
Tetrahydrocannabinols
or
synthetic
equivalents
of
the
substances
5
contained
in
the
plant,
or
in
the
resinous
extractives
of
Cannabis,
sp.
6
and/or
synthetic
substances,
derivatives,
and
their
isomers
with
simi
-
7
lar
chemical
structure
such
as
the
following:
8
i.
Tetrahydrocannabinols,
except
for
the
permitted
amount
of
9
tetrahydrocannabinol
found
in
industrial
hemp,
or
nabiximols
in
a
10
drug
product
approved
by
the
United
States
food
and
drug
adminis
-
1
1
tration:
12
a.
∆
1
cis
or
trans
tetrahydrocannabinol,
and
their
opti
-
13
cal
isomers,
excluding
dronabinol
in
sesame
oil
and
encapsu
-
14
lated
in
either
a
soft
gelatin
capsule
or
in
an
oral
solution
15
in
a
drug
product
approved
by
the
U.S.
Food
and
Drug
Adminis
-
16
tration.
17
b.
∆
6
cis
or
trans
tetrahydrocannabinol,
and
their
optical
18
isomers.
19
c.
∆
3
,
4
cis
or
trans
tetrahydrocannabinol,
and
its
optical
20
isomers.
(Since
nomenclature
of
these
substances
is
not
in
-
21
ternationally
standardized,
compounds
of
these
structures,
22
regardless
of
numerical
designation
of
atomic
positions
are
23
covered.)
24
d.
[(6aR,10aR)
-
9
-
(hydroxymethyl)
-
6,6
-
dimethyl
-
3
-
(2methy
-
25
loctan
-
2
-
yl)
-
6a,7,10,10a
-
tetrahydrobenzo[c]chromen
-
26
1
-
o1)],
also
known
as
6aR
-
trans
-
3
-
(1,1
-
dimethylhep
-
27
tyl)
-
6a,7,10,10a
-
tetrahydro
-
1
-
hydroxy
-
6,6
-
dimethyl
-
6H
-
28
dibenzo[b,d]pyran
-
9
-
methanol
(HU
-
210)
and
its
geometric
29
isomers
(HU211
or
dexanabinol).
30
ii.
The
following
synthetic
drugs:
31
a.
Any
compound
structurally
derived
from
(1H
-
indole
-
3
-
32
yl)(cycloalkyl,
cycloalkenyl,
aryl)methanone,
or
(1H
-
in
-
33
dole
-
3
-
yl)(cycloalkyl,
cycloalkenyl,
aryl)methane,
or
34
(1H
-
indole
-
3
-
yl)(cycloalkyl,
cycloalkenyl,
aryl
)
,
methyl
35
or
dimethyl
butanoate,
amino
-
methyl
(or
dimethyl)
-
1
-
oxobu
-
36
tan
-
2
-
yl)
carboxamide
by
substitution
at
the
nitrogen
atoms
37
of
the
indole
ring
or
carboxamide
to
any
extent,
whether
or
38
not
further
substituted
in
or
on
the
indole
ring
to
any
ex
-
39
tent,
whether
or
not
substituted
to
any
extent
in
or
on
the
40
cycloalkyl,
cycloalkenyl,
aryl
ring(s)
(substitution
in
the
41
ring
may
include,
but
is
not
limited
to,
heteroatoms
such
as
42
nitrogen,
sulfur
and
oxygen).
43
b.
N
-
(1
-
amino
-
3
-
methyl
-
1
-
oxobutan
-
2
-
yl)
-
1
-
(5
-
fluo
-
44
ropentyl)
-
1
H
-
indazole
-
3
-
carboxamide
(5F
-
AB
-
PINACA).
45
c.
1
-
(1.3
-
benzodioxol
-
5
-
yl)
-
2
-
(ethylamino)
-
pentan
-
1
-
one
46
(
N
-
ethylpentylone
,
(
ephylone).
47
d.
1
-
(4
-
cyanobutyl)
-
N
-
(2
-
phenylpropan
-
2
-
yl)
-
1
H
-
inda
-
48
zole
-
3
-
carboxamide
(4
-
cn
-
cumyl
-
BUTINACA).
49

8
e.
5
-
pentyl
-
2
-
(2
-
phenylpropan
-
2
-
yl)pyrido[4,3
-
b]indol
-
1
-
1
one
(Cumyl
PeGACLONE
Pegaclone
).
2
f.
Ethyl
2
-
(1
-
(5
-
fluoropentyl)
-
1H
-
indazole
-
3carboxam
-
3
ido)
-
3,3
-
dimethylbutanoate
*
(5F
-
EDMB
-
PINACA).
4
g.
Ethyl
2
-
(1
-
(5
-
fluoropentyl)
-
1H
-
indole
-
3
-
carboxamido)
-
5
3,3
-
dimethylbutanoate
(5F
-
EDMB
-
PICA).
6
h.
(1
-
(4
-
fluorobenzyl)
-
1H
-
indol
-
3
-
yl)(2,2,3,3tetram
-
7
ethylcyclopropyl)methanone
(FUB
-
144).
8
i.
1
-
(5
-
fluoropentyl)
-
N
-
(2
-
phenylpropan
-
2
-
yl)
-
1H
-
inda
-
9
zole
-
3
-
carboxamide
(5f
-
cumyl
-
pinaca;
SGT
-
25).
10
j.
(1
-
(5
-
fluoropentyl)
-
N
-
(2
-
phenylpropan
-
2
-
yl)
-
1
1
1
H
-
pyrrolo[2.3
-
B]pyridine
-
3
-
carboxamide(5fcumyl
-
P7AICA).
12
k.
FUB
-
AMB,
MMB
-
FUBINACA
(Methyl
2
-
(1
-
(4
-
fluoroben
-
13
zyl)
-
1H
-
indazole
-
3
-
carboxamido)
-
3
-
methylbutanoate.
14
l.
MMB
-
FUBICA
(Methyl
2
-
(1
-
(4
-
Fluorobenzyl)
-
1H
-
Indole
-
3
-
15
carboxamido)
-
3
-
methyl
butanoate).
16
m.
Methyl
3,3
-
dimethyl
-
2
-
((1
-
(pent
-
4
-
en
-
1
-
yl)
-
1H
-
in
-
17
dazol
e
-
3
-
yl)formamido
carboxamido
)butanoate
(MDMB
-
4EN
-
18
PINACA).
19
n.
Methyl
2
-
(1
-
(cyclohexylmethyl)
-
1H
-
indole
-
3
-
carboxam
-
20
ido)
-
3
-
methylbutanoate
(MMB
-
CHMICA,
AMB
-
CHMICA).
21
o.
Methyl
2
-
(1
-
(cyclohexylmethyl)
-
1H
-
indole
-
3
-
carboxam
-
22
ido)
-
3,3
-
dimethylbutanoate
(MDMB
-
CHMICA
,
MMB
-
CHMINACA
).
23
p.
Methyl
2
-
(1
-
(4
-
fluorobenzyl)
-
1H
-
indazole
-
3
-
carboxam
-
24
ido
-
3,3
-
dimethylbutanoate
(MDMB
-
FUBINACA).
25
q.
Methyl
2
-
[[1
-
(4
-
Fluorobutyl)Indole
-
3
-
Carbonyl]Amino]
-
26
3,3
-
Dimethyl
-
Butanoate
(4F
-
MDMB
-
BUTICA
,
4F
-
MDMB
-
BICA
).
27
r.
Methyl
2
-
(1
-
(5
-
fluoropentyl)
-
1H
-
indole
-
3
-
carboxam
-
28
ido)
-
3,3
-
dimethylbutanoate
(5F
-
MDMB
-
PICA
,
5F
-
MDMB
-
2201
).
29
s.
Methyl
2
-
(1
-
(5
-
fluoropentyl)
-
1H
-
indazole
-
3
-
carboxam
-
30
ido)
-
3,3
-
dimethylbutanoate
(5F
-
ADB,
5F
-
MDMB
-
PINACA).
31
t.
Methyl
2
-
(1
-
(5
-
fluoropentyl)
-
1H
-
indazole
-
3
-
carboxam
-
32
ido)
-
3
-
methylbutanoate
(5F
-
AMB).
33
u.
N
-
(1
-
Amino
-
3,3
-
dimethyl
-
1
-
oxobutan
-
2
-
yl)
-
1
-
butyl
-
1H
-
34
Indazole
-
3
-
carboxamide
(ADB
-
BUTINACA).
35
v.
N
-
(1
-
amino
-
3,3
-
dimethyl
-
1
-
oxobutan
-
2
-
yl)
-
1
-
(4
-
fluo
-
36
robenzyl)
-
1H
-
indazole
-
3
-
carboxamide
(ADB
-
FUBINACA).
37
w.
N
-
(1
-
Amino
-
3,3
-
dimethyl
-
1
-
oxobutan
-
2
-
yl)
-
1
-
(pent
-
4
-
38
en
-
1
-
yl)
-
1H
-
indazole
-
3
-
carboxamide
(ADB
-
4EN
-
PINACA).
39
x.
N
-
(adamantan
-
1
-
yl)
-
1
-
(4
-
fluorobenzyl)
-
1H
-
indazole
-
3
-
40
carboxamide
(FUB
-
AKB48;
FUB
-
APINACA).
41
y.
N
-
(adamantan
-
1
-
yl)
-
1
-
(5
-
fluoropentyl)
-
1H
-
indazole
-
3
-
42
carboxamide
(5F
-
APINACA,
5F
-
AKB48).
43
z.
N
-
(1
-
amino
-
3
-
methyl
-
1
-
oxobutan
-
2
-
yl)1
-
(Cyclohexyl
-
44
methyl)
-
1H
-
indazole
-
3
-
carboxamide
(AB
-
CHMINACA).
45
aa.
Naphthalen
-
1
-
yl
1
-
(5
-
fluoropentyl)
-
1H
-
indole
-
3
-
car
-
46
boxylate
(NM2201;
CBL2201).
47
bb.
Any
compound
structurally
derived
from
3
-
(1
-
naph
-
48
thoyl)pyrrole
by
substitution
at
the
nitrogen
atom
of
the
49
pyrrole
ring
to
any
extent,
whether
or
not
further
sub
-
50

9
stituted
in
the
pyrrole
ring
to
any
extent,
whether
or
not
1
substituted
in
the
naphthyl
ring
to
any
extent.
2
cc.
Any
compound
structurally
derived
from
1
-
(1
-
naphthyl
-
3
methyl)indene
by
substitution
at
the
3
-
position
of
the
in
-
4
dene
ring
to
any
extent,
whether
or
not
further
substituted
5
in
the
indene
ring
to
any
extent,
whether
or
not
substituted
6
in
the
naphthyl
ring
to
any
extent.
7
dd.
Any
compound
structurally
derived
from
3
-
pheny
-
8
lacetylindole
by
substitution
at
the
nitrogen
atom
of
the
9
indole
ring
to
any
extent,
whether
or
not
further
substi
-
10
tuted
in
the
indole
ring
to
any
extent,
whether
or
not
sub
-
1
1
stituted
in
the
phenyl
ring
to
any
extent.
12
ee.
Any
compound
structurally
derived
from
2
-
(3
-
hydroxy
-
13
cyclohexyl)phenol
by
substitution
at
the
5
-
position
of
the
14
phenolic
ring
to
any
extent,
whether
or
not
substituted
in
15
the
cyclohexyl
ring
to
any
extent.
16
ff.
Any
compound
structurally
derived
from
3
-
(benzoyl)in
-
17
dole
structure
with
substitution
at
the
nitrogen
atom
of
18
the
indole
ring
to
any
extent,
whether
or
not
further
sub
-
19
stituted
in
the
indole
ring
to
any
extent
and
whether
or
not
20
substituted
in
the
phenyl
ring
to
any
extent.
21
gg.
[2,3
-
dihydro
-
5
-
methyl
-
3
-
(4
-
morpholinyl
-
22
methyl)pyrrolo[1,2,3
-
de]
-
1,4
-
benzoxazin
-
6
-
yl]
-
1
-
23
napthalenylmethanone
(WIN
-
55,212
-
2).
24
hh.
3
-
dimethylheptyl
-
11
-
hydroxyhexahydrocannabinol
(HU
-
25
243).
26
ii.
[(6S,
6aR,
9R,
10aR)
-
9
-
hydroxy
-
6
-
methyl
-
3
-
[(2R)
-
27
5
-
phenylpentan
-
2
-
yl]oxy
-
5,6,6a,7,8,9,10,10a
-
octahy
-
28
drophenanthridin
-
1
-
yl]acetate
(CP
50,5561).
29
(30)
Ethylamine
analog
of
phencyclidine:
N
-
ethyl
-
1
-
phenylcy
-
30
clohexylamine
(1
-
phenylcyclohexyl)
ethylamine;
N
-
(1
-
phenylcy
-
31
clohexyl)
ethylamine,
cyclohexamine,
PCE;
32
(31)
Pyrrolidine
analog
of
phencyclidine:
1
-
(phenylcyclohexyl)
-
33
pyrrolidine,
PCPy,
PHP;
34
(32)
Thiophene
analog
of
phencyclidine
1
-
[1
-
(2
-
thienyl)
-
cyclohexyl]
-
35
piperidine,
2
-
thienylanalog
of
phencyclidine,
TPCP,
TCP;
36
(33)
Thiofuranyl
fentanyl;
37
(34)
(33)
1
-
[1
-
(2
-
thienyl)
cyclohexyl]
pyrrolidine
another
name:
38
TCPy;
39
(35)
(34)
Spores
or
mycelium
capable
of
producing
mushrooms
that
con
-
40
tain
psilocybin
or
psilocin.
41
(e)
Unless
specifically
excepted
or
unless
listed
in
another
schedule,
42
any
material,
compound,
mixture
or
preparation
which
contains
any
quantity
43
of
the
following
substances
having
a
depressant
effect
on
the
central
ner
-
44
vous
system,
including
its
salts,
isomers,
and
salts
of
isomers
whenever
the
45
existence
of
such
salts,
isomers,
and
salts
of
isomers
is
possible
within
the
46
specific
chemical
designation:
47
(1)
Bromazolam;
48
(1)
(2)
Clonazolam;
49
(2)
(3)
Diclazepam;
50

10
(3)
(4)
Gamma
hydroxybutyric
acid
(
some
other
names
include
GHB;
gam
-
1
ma
-
hydroxybutyrate,
4
-
hydroxybutyrate;
4
-
hyroxybutanoic
acid;
sod
-
2
ium
oxybate;
sodium
oxybutyrate);
3
(4)
(5)
Etizolam;
4
(5)
(6)
Flualprazolam;
5
(6)
(7)
Flubromazolam;
6
(7)
(8)
Flunitrazepam
(also
known
as
R2,
Rohypnol);
7
(8)
(9)
Mecloqualone;
8
(9)
(10)
Methaqualone.
9
(f)
Stimulants.
Unless
specifically
excepted
or
unless
listed
in
an
-
10
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
1
1
tains
any
quantity
of
the
following
substances
having
a
stimulant
effect
on
12
the
central
nervous
system,
including
its
salts,
isomers,
and
salts
of
iso
-
13
mers:
14
(1)
Amineptine
(7
-
[(10,11
-
dihydro
-
5H
-
dibenzo[a,d]cyclohepten
-
5
-
15
yl)amino]heptanoic
acid)
;
16
(2)
Aminorex
(some
other
names:
(
aminoxaphen
)
,
2
-
amino
-
5
-
phenyl
-
2
-
17
oxazoline,
or
4,5
-
dihydro
-
5
-
phenyl
-
2
-
oxazolamine),
4,4'
-
dimethylam
-
18
inorex
(4,4'
-
DMAR;
4,5
-
dihydro
-
4
-
methyl
-
5
-
(4
-
methylphenyl)
-
2
-
oxazo
-
19
lamine)
or
(4,5
-
dihydro
-
5
-
phenyl
-
2
-
oxazolamine)
;
20
(3)
Cathinone
(
some
other
names:
2
-
amino
-
1
-
phenol
-
1
-
propanone,
alp
-
21
ha
-
aminopropiophenone,
2
-
aminopropiophenone
and
norephedrone);
22
(4)
Substituted
cathinones.
Any
compound,
except
bupropion
or
com
-
23
pounds
listed
under
a
different
schedule,
structurally
derived
from
24
2
-
aminopropan
-
1
-
one
by
substitution
at
the
1
-
position
with
either
25
phenyl,
naphthyl
or
thiophene
ring
systems,
whether
or
not
the
compound
26
is
further
modified
in
any
of
the
following
ways:
27
i.
By
substitution
in
the
ring
system
to
any
extent
with
alkyl,
28
alkylenedioxy,
alkoxy,
haloalkyl,
hydroxyl
or
halide
sub
-
29
stituents,
whether
or
not
further
substituted
in
the
ring
system
30
by
one
(1)
or
more
other
univalent
substituents;
31
ii.
By
substitution
at
the
3
-
position
with
an
acyclic
alkyl
sub
-
32
stituent;
33
iii.
By
substitution
at
the
2
-
amino
nitrogen
atom
with
alkyl,
34
dialkyl,
benzyl
or
methoxybenzyl
groups,
or
by
inclusion
of
the
35
2
-
amino
nitrogen
atom
in
a
cyclic
structure.
36
(5)
Alpha
-
pyrrolidinoheptaphenone
*
(PV8);
37
(6)
Alpha
-
pyrrolidinohexanophenone
*
(A
-
PHP);
38
(7)
4
-
chloro
-
alpha
-
pyrrolidinovalerophenone
*
(4
-
chloro
-
a
-
pvp);
39
(8)
Ethylphenidate;
40
(8)
(9)
Eutylone
(1
-
(1,3
-
benzodioxol
-
5
-
yl)
-
2
-
(ethylamino)bu
-
41
tan
-
1
-
one)
(bk
-
EBDB)
;
42
(9)
(10)
Fenethylline;
43
(10)
(11)
Mesocarb
(N
-
phenyl
-
N'
-
(3
-
(1
-
phenylpropan
-
2
-
yl)
-
1,2,3
-
oxa
-
44
diazol
-
3
-
ium
-
5
-
yl)carbamimidate)
;
45
(11)
(12)
Methcathinone
(
some
other
names:
2
-
(methyl
-
amino)
-
pro
-
46
piophenone,
alpha
-
(methylamino)
-
propiophenone,
N
-
methylcathin
-
47
one,
AL
-
464,
AL
-
422,
AL
-
463
and
UR1423);
48
(12)
(13)
Methiopropamine
(N
-
methyl
-
1
-
(thiophen
-
2
-
yl)propan
-
2
-
49
amine)
;
50

11
(13)
(14)
(+/
-)cis
-
4
-
methylaminorex
[(+/
-)cis
-
4,5
-
dihydro
-
4
-
meth
-
1
yl
-
5
-
phenyl
-
2
-
oxazolamine]
;
2
(14)
(15)
4
-
methyl
-
alpha
-
ethylaminopentiophenone
*
(4
-
MEAP);
3
(15)
(16)
4'
-
methyl
-
alpha
-
pyrrolidinohexiophenone
*
(MPHP);
4
(16)
(17)
2
-
(methylamino)
-
1
-
(3
-
methylphenyl)propan
-
1
-
one
(3
-
MMC);
5
(17)
(18)
4
-
methyl
-
1
-
phenyl
-
2
-
(pyrrolidine
-
1
-
yl)pent
-
1
-
one)
(ALPHA
-
6
PIHP);
7
(18)
(19)
N
-
benzylpiperazine
(
also
known
as:
BZP,
1
-
benzylpiper
-
8
azine);
9
(19)
(20)
N
-
ethylamphetamine;
10
(20)
(21)
N
-
ethylhexedrone
*
;
1
1
(21)
(22)
N,N
-
dimethylamphetamine
(also
known
as:
N,N
-
alpha
-
12
trimethyl
-
benzeneethanamine)
.
13
SECTION
2.
That
Section
37
-
2707,
Idaho
Code,
be,
and
the
same
is
hereby
14
amended
to
read
as
follows:
15
37
-
2707.
SCHEDULE
II.
(a)
Schedule
II
shall
consist
of
the
drugs
and
16
other
substances,
by
whatever
official
name,
common
or
usual
name,
chemical
17
name,
or
brand
name
designated,
listed
in
this
section.
18
(b)
Substances,
vegetable
origin
or
chemical
synthesis.
Unless
19
specifically
excepted
or
unless
listed
in
another
schedule,
any
of
the
fol
-
20
lowing
substances
whether
produced
directly
or
indirectly
by
extraction
21
from
substances
of
vegetable
origin,
or
independently
by
means
of
chemical
22
synthesis,
or
by
a
combination
of
extraction
and
chemical
synthesis:
23
(1)
Opium
and
opiate,
and
any
salt,
compound,
derivative,
or
prepa
-
24
ration
of
opium
or
opiate,
excluding
apomorphine,
dextrorphan,
nal
-
25
buphine,
naldemedine,
nalmefene,
naloxegol,
6β
-
naltexol,
naloxone,
26
naltrexone
,
samidorphan,
and
their
respective
salts,
but
including
the
27
following:
28
1.
i.
Raw
opium;
29
2.
ii.
Opium
extracts;
30
3.
iii.
Opium
fluid
extracts;
31
4.
iv.
Powdered
opium;
32
5.
v.
Granulated
opium;
33
6.
vi.
Tincture
of
opium;
34
7.
vii.
Codeine;
35
8.
viii.
Dihydroetorphine;
36
9.
ix.
Diprenorphine;
37
10.
x.
Ethylmorphine;
38
11.
xi.
Etorphine
hydrochloride;
39
12.
xii.
Hydrocodone;
40
13.
xiii.
Hydromorphone;
41
14.
xiv.
Metopon;
42
15.
xv.
Morphine;
43
xvi.
Noroxymorphone;
44
16.
xvii.
Oripavine;
45
17.
xviii.
Oxycodone;
46
18.
xix.
Oxymorphone;
47
19.
Tapentadol;
48
20.
xx.
Thebaine.
49

12
(2)
Any
salt,
compound,
derivative,
or
preparation
thereof
which
is
1
chemically
equivalent
or
identical
with
any
of
the
substances
referred
2
to
in
paragraph
(1)
of
this
subsection,
except
that
these
substances
3
shall
not
include
the
isoquinoline
alkaloids
of
opium.
4
(3)
Opium
poppy
and
poppy
straw.
5
(4)
Coca
leaves
and
any
salt,
compound,
derivative,
or
preparation
6
of
coca
leaves,
and
any
salt,
compound,
derivative,
or
preparation
7
thereof
which
is
chemically
equivalent
or
identical
with
any
of
these
8
substances,
but
shall
not
include
the
following:
9
1.
i.
Decocainized
coca
leaves
or
extractions
of
coca
leaves,
10
which
extractions
do
not
contain
cocaine;
or
ecgonine;
or
1
1
2.
ii.
[
1
2
3
I]ioflupane.
12
(5)
Benzoylecgonine.
13
(6)
Methylbenzoylecgonine
(
Cocaine
,
-
its
salts,
optical
and
geometric
14
isomers,
and
salts
of
optical
and
geometric
isomers
)
.
15
(7)
Concentrate
of
poppy
straw
(the
crude
extract
of
poppy
straw
in
liq
-
16
uid,
solid
or
powder
form
that
contains
the
phenanthrine
alkaloids
of
17
the
opium
poppy).
18
(c)
Any
of
the
following
opiates,
including
their
isomers,
esters,
19
ethers,
salts,
and
salts
of
isomers,
whenever
the
existence
of
these
iso
-
20
mers,
esters,
ethers
and
salts
is
possible
within
the
specific
chemical
21
designation,
unless
specifically
excepted
or
unless
listed
in
another
22
schedule:
23
(1)
Alfentanil;
24
(2)
Alphaprodine;
25
(3)
Anileridine;
26
(4)
Bezitramide;
27
(5)
Bulk
Dextropropoxyphene
(nondosage
forms);
28
(6)
Carfentanil;
29
(7)
Dihydrocodeine;
30
(8)
Diphenoxylate;
31
(9)
Fentanyl;
32
(10)
Isomethadone;
33
(11)
Levo
-
alphacetylmethadol
(
also
known
as
levo
-
alpha
-
acetylmet
-
34
hadol,
levomethadyl
acetate,
LAAM);
35
(12)
Levomethorphan;
36
(13)
Levorphanol;
37
(14)
Metazocine;
38
(15)
Methadone;
39
(16)
Methadone
-
-
Intermediate,
4
-
cyano
-
2
-
dimethylamino
-
4,
4
-
diphenyl
40
butane;
41
(17)
Moramide
-
-
Intermediate,
2
-
methyl
-
3
-
morpholino
-
1,
1
-
diphenyl
42
propane
-
carboxylic
acid;
43
(18)
Norfentanyl
(N
-
phenyl
-
N
-
(piperidin
-
4
-
yl)
propionamide);
44
(19)
(18)
Oliceridine;
45
(20)
(19)
Pethidine
(meperidine);
46
(21)
(20)
Pethidine
-
-
Intermediate
-
-
A,
4
-
cyano
-
1
-
methyl
-
4
-
phenyl
-
47
piperidine;
48
(22)
(21)
Pethidine
-
-
Intermediate
-
-
B,
ethyl
-
4
-
phenylpiperid
-
49
ine
-
4
-
carboxylate;
50

13
(23)
(22)
Pethidine
-
-
Intermediate
-
-
C,
1
-
methyl
-
4
-
phenylpiperid
-
1
ine
-
4
-
carboxylic
acid;
2
(24)
(23)
Phenazocine;
3
(25)
(24)
Piminodine;
4
(26)
(25)
Racemethorphan;
5
(27)
(26)
Racemorphan;
6
(28)
(27)
Remifentanil;
7
(29)
(28)
Sufentanil
.
;
8
(29)
Tapentadol;
9
(30)
Thiafentanil.
10
(d)
Stimulants.
Unless
specifically
excepted
or
unless
listed
in
an
-
1
1
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
12
tains
any
quantity
of
the
following
substances
having
a
stimulant
effect
on
13
the
central
nervous
system:
14
(1)
Amphetamine,
its
salts,
optical
isomers,
and
salts
of
its
optical
15
isomers;
16
(2)
Lisdexamfetamine
,
its
salts,
isomers,
and
salts
of
its
isomers
;
17
(3)
Methamphetamine,
its
salts,
isomers,
and
salts
of
its
isomers;
18
(4)
Phenmetrazine
and
its
salts;
19
(5)
Methylphenidate.
20
(e)
Depressants.
Unless
specifically
excepted
or
unless
listed
in
an
-
21
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
22
tains
any
quantity
of
the
following
substances
having
a
depressant
effect
on
23
the
central
nervous
system,
including
its
salts,
isomers,
and
salts
of
iso
-
24
mers,
whenever
the
existence
of
such
salts,
isomers,
and
salts
of
isomers
is
25
possible
within
the
specific
chemical
designation:
26
(1)
Amobarbital;
27
(2)
Glutethimide;
28
(3)
Pentobarbital;
29
(4)
Phencyclidine;
30
(5)
Secobarbital.
31
(f)
Hallucinogenic
substances.
32
(1)
Nabilone
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
(another
name
for
nabilone:
33
(+/
-)
-
trans
-
3
-
(1,1
-
dimethylheptyl)
-
6,6a,7,8,10,10a
-
hexahydro
-
1
-
hy
-
34
droxy
-
6,6
-
dimethyl
-
9H
-
dibenzo[b,d]pyran
-
9
-
one)
(21
CFR
1308.12
(f))
.
35
(g)
Immediate
precursors.
Unless
specifically
excepted
or
unless
36
listed
in
another
schedule,
any
material,
compound,
mixture,
or
preparation
37
which
contains
any
quantity
of
the
following
substances:
38
(1)
Immediate
precursor
to
amphetamine
and
methamphetamine:
39
(a)
i.
Anthranilic
acid;
40
(b)
ii.
Ephedrine;
41
(c)
iii.
Lead
acetate;
42
(d)
iv.
Methylamine;
43
(e)
v.
Methyl
formamide;
44
(f)
vi.
N
-
methylephedrine;
45
(g)
vii.
Phenylacetic
acid;
46
(h)
viii.
Phenylacetone
(phenyl
-
2
-
propanone,
P2P)
;
47
(i)
ix.
Phenylpropanolamine;
48
(j)
x.
Pseudoephedrine.
49

14
Except
that
any
combination
or
compound
containing
ephedrine,
or
any
of
1
its
salts
and
isomers,
or
phenylpropanolamine
or
its
salts
and
isomers,
2
or
pseudoephedrine,
or
any
of
its
salts
and
isomers
which
is
prepared
3
for
dispensing
or
over
-
the
-
counter
distribution
is
not
a
controlled
4
substance
for
the
purpose
of
this
section,
unless
such
substance
is
pos
-
5
sessed,
delivered,
or
possessed
with
intent
to
deliver
to
another
with
6
the
intent
to
manufacture
methamphetamine,
amphetamine
or
any
other
7
controlled
substance
in
violation
of
section
37
-
2732,
Idaho
Code.
For
8
purposes
of
this
provision,
the
requirements
of
the
uniform
controlled
9
substances
act
shall
not
apply
to
a
manufacturer,
wholesaler
or
re
-
10
tailer
of
over
-
the
-
counter
products
containing
the
listed
substances
1
1
unless
such
person
possesses,
delivers,
or
possesses
with
intent
to
12
deliver
to
another
the
over
-
the
-
counter
product
with
intent
to
manufac
-
13
ture
a
controlled
substance.
14
(2)
Immediate
precursors
to
phencyclidine
(PCP):
15
(a)
i.
1
-
phenylcyclohexylamine;
16
(b)
ii.
1
-
piperidinocyclohexanecarbonitrile
(PCC).
17
(3)
Immediate
precursor
s
to
fentanyl:
18
i.
4
-
anilino
-
N
-
phenethyl
-
4
-
piperidine
(ANPP)
.
;
19
ii.
Norfentanyl.
20
SECTION
3.
That
Section
37
-
2709,
Idaho
Code,
be,
and
the
same
is
hereby
21
amended
to
read
as
follows:
22
37
-
2709.
SCHEDULE
III.
(a)
Schedule
III
shall
consist
of
the
drugs
and
23
other
substances,
by
whatever
official
name,
common
or
usual
name,
chemical
24
name,
or
brand
name
designated,
listed
in
this
section.
25
(b)
Stimulants.
Unless
specifically
excepted
or
unless
listed
in
an
-
26
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
27
tains
any
quantity
of
the
following
substances
having
a
stimulant
effect
on
28
the
central
nervous
system,
including
its
salts,
isomers,
(whether
optical
,
29
positional,
or
geometric),
and
salts
of
such
isomers
whenever
the
existence
30
of
such
salts,
isomers,
and
salts
of
isomers
is
possible
within
the
specific
31
chemical
designation:
32
(1)
Those
compounds,
mixtures,
or
preparations
in
dosage
unit
form
con
-
33
taining
any
stimulant
substances
listed
in
schedule
II
which
compounds,
34
mixtures,
or
preparations
were
listed
as
excepted
compounds
under
21
35
CFR
1308.32,
and
any
other
drug
of
the
quantitative
composition
shown
in
36
that
list
for
those
drugs
or
which
is
the
same
except
that
it
contains
a
37
lesser
quantity
of
controlled
substances.
38
(2)
Benzphetamine;
39
(3)
Chlorphentermine;
40
(4)
Clortermine;
41
(5)
Phendimetrazine.
42
(c)
Depressants.
Unless
listed
in
another
schedule,
any
material,
com
-
43
pound,
mixture,
or
preparation
which
contains
any
quantity
of
the
following
44
substances
having
a
potential
for
abuse
associated
with
a
depressant
effect
45
on
the
central
nervous
system:
46
(1)
Any
compound,
mixture
or
preparation
containing
the
following
sub
-
47
stances
or
any
salt
thereof
and
one
(1)
or
more
other
active
medicinal
48
ingredients
that
are
not
listed
in
any
schedule
:
49

15
i.
Amobarbital;
1
ii.
Secobarbital;
2
iii.
Pentobarbital
or
any
salt
thereof
and
one
(1)
or
more
other
3
active
medicinal
ingredients
which
are
not
listed
in
any
schedule
.
4
(2)
Any
suppository
dosage
form
containing
the
following
substances
or
5
any
salt
of
any
of
these
drugs
and
approved
by
the
food
and
drug
adminis
-
6
tration
for
marketing
only
as
a
suppository
:
7
i.
Amobarbital;
8
ii.
Secobarbital;
9
iii.
Pentobarbital
or
any
salt
of
any
of
these
drugs
and
approved
10
by
the
Food
and
Drug
Administration
for
marketing
only
as
a
suppos
-
1
1
itory
.
12
(3)
Any
substance
which
contains
any
quantity
of
a
derivative
of
barbi
-
13
turic
acid
or
any
salt
thereof,
including,
but
not
limited
to:
14
i.
Aprobarbital;
15
ii.
Butabarbital
(secbutabarbital);
16
iii.
Butalbital,
excluding
drug
products
exempted
by
the
federal
17
drug
enforcement
administration
(DEA);
18
iv.
Butobarbital
(butethal);
19
v.
Talbutal;
20
vi.
Thiamylal;
21
vii.
Thiopental;
22
viii.
Vinbarbital.
23
(4)
Chlorhexadol;
24
(5)
Embutramide;
25
(6)
Any
drug
product
containing
gamma
hydroxybutyric
acid
(GHB)
,
in
-
26
cluding
its
salts,
isomers,
and
salts
of
isomers,
for
which
an
applica
-
27
tion
is
approved
under
section
505
of
the
federal
food,
drug,
and
cos
-
28
metic
act;
29
(7)
Ketamine,
its
salts,
isomers,
and
salts
of
isomers
-
30
7285.
(Some
other
names
for
ketamine:
(+/
-)
-
2
-
(2
-
chlorophenyl)
-
2
-
31
(methylamino)
-
cyclohexanone)
.
32
(8)
Lysergic
acid;
33
(9)
Lysergic
acid
amide
(LSA,
LAA)
;
34
(10)
Methyprylon;
35
(11)
Perampanel,
and
its
salts,
isomers
and
salts
of
isomers;
36
(12)
Sulfondiethylmethane;
37
(13)
Sulfonethylmethane;
38
(14)
Sulfonmethane;
39
(15)
Tiletamine
and
zolazepam
or
any
salt
thereof.
40
(d)
Nalorphine.
41
(e)
Narcotic
drugs.
Unless
specifically
excepted
or
unless
listed
in
42
another
schedule:
43
(1)
Any
material,
compound,
mixture,
or
preparation
containing
limited
44
quantities
of
any
of
the
following
narcotic
drugs,
or
any
salts
thereof:
45
(i)
i.
Not
more
than
1.8
grams
of
codeine,
or
any
of
its
salts,
46
per
100
milliliters
or
not
more
than
90
milligrams
per
dosage
unit,
47
with
an
equal
or
greater
quantity
of
an
isoquinoline
alkaloid
of
48
opium;
49

16
(ii)
ii.
Not
more
than
1.8
grams
of
codeine,
or
any
of
its
salts,
1
per
100
milliliters
or
not
more
than
90
milligrams
per
dosage
unit,
2
with
one
(1)
or
more
active,
nonnarcotic
ingredients
in
recognized
3
therapeutic
amounts;
4
(iii)
iii.
Not
more
than
1.8
grams
of
dihydrocodeine,
or
any
of
5
its
salts,
per
100
milliliters
or
not
more
than
90
milligrams
per
6
dosage
unit,
with
one
(1)
or
more
active,
nonnarcotic
ingredients
7
in
recognized
therapeutic
amounts;
8
(iv)
iv.
Not
more
than
300
milligrams
of
ethylmorphine,
or
any
of
9
its
salts,
per
100
milliliters
or
not
more
than
15
milligrams
per
10
dosage
unit,
with
one
(1)
or
more
active,
nonnarcotic
ingredients
1
1
in
recognized
therapeutic
amounts;
12
(v)
v.
Not
more
than
500
milligrams
of
opium
per
100
milliliters
13
or
per
100
grams,
or
not
more
than
25
milligrams
per
dosage
unit,
14
with
one
(1)
or
more
active,
nonnarcotic
ingredients
in
recognized
15
therapeutic
amounts;
16
(vi)
vi.
Not
more
than
50
milligrams
of
morphine,
or
any
of
its
17
salts,
per
100
milliliters
or
per
100
grams
with
one
(1)
or
more
ac
-
18
tive,
nonnarcotic
ingredients
in
recognized
therapeutic
amounts.
19
(2)
Any
material,
compound,
mixture,
or
preparation
containing
any
of
20
the
following
narcotic
drugs
or
their
salts,
as
set
forth
below:
21
(i)
i.
Buprenorphine.
22
(ii)
ii.
[Reserved].
23
(f)
Anabolic
steroids
and
human
growth
hormones.
Any
drug
or
hormonal
24
substance,
chemically
and
pharmacologically
related
to
testosterone
(other
25
than
estrogens,
progestins
and
corticosteroids)
that
promotes
muscle
growth
26
including
any
salt,
ester
or
isomer
of
a
drug
or
substance
listed
in
this
sub
-
27
section,
if
that
salt,
ester
or
isomer
promotes
muscle
growth.
28
(1)
13beta
-
ethyl
-
17beta
-
hydroxygon
-
4
-
en
-
3
-
one;
29
(2)
17alpha
-
methyl
-
3alpha,
17beta
-
dihydroxy
-
5alpha
-
androstane;
30
(3)
17alpha
-
methyl
-
3beta,
17beta
-
dihydroxy
-
5alpha
-
androstane;
31
(4)
17alpha
-
methyl
-
3beta,
17beta
-
dihydroxyandrost
-
4
-
ene;
32
(5)
17alpha
-
methyl
-
4
-
hydroxynandrolone;
33
(6)
17alpha
-
methyl
-
5alpha
-
androstan
-
17beta
-
ol;
34
(7)
17alpha
-
methyl
-
androst
-
2
-
ene
-
3,17beta
-
diol;
35
(8)
17alpha
-
methyl
-
androsta
-
1,4
-
diene
-
3,17beta
-
diol;
36
(9)
17alpha
-
methyl
-
androstan
-
3
-
hydroxyimine
-
17beta
-
ol;
37
(10)
17alpha
-
methyl
-
delta1
-
dihydrotestosterone;
38
(11)
17beta
-
hydroxy
-
androstano[
2,3
3,2
-
c]isoxazole;
39
(12)
17beta
-
hydroxy
-
androstano[2,3
-
d]isoxazole;
40
(13)
18alpha
-
homo
-
3
-
hydroxy
-
estra
-
2,5(10)
-
dien
-
17
-
one;
41
(14)
19
-
nor
-
4
-
androstenediol;
42
(15)
19
-
nor
-
4
-
androstenedione;
43
(16)
19
-
nor
-
4,9(10)
-
androstadienedione;
44
(17)
19
-
nor
-
5
-
androstenediol;
45
(18)
19
-
nor
-
5
-
androstenedione;
46
(19)
1
-
androstenediol;
47
(20)
1
-
androstenedione;
48
(21)
2alpha,17alpha
-
dimethyl
-
17beta
-
hydroxy
-
5beta
-
androstan
-
3
-
one;
49

17
(22)
2alpha,3alpha
-
epithio
-
17alpha
-
methyl
-
5alpha
-
androstan
-
17beta
-
1
ol;
2
(23)
[3,2
-
c]furazan
-
5alpha
-
androstan
-
17beta
-
ol;
3
(24)
[3,2
-
c]pyrazole
-
androst
-
4
-
en
-
17beta
-
ol;
4
(25)
3alpha,17beta
-
dihydroxy
-
5alpha
-
androstane;
5
(26)
3beta,17beta
-
dihydroxy
-
5alpha
-
androstane;
6
(27)
3beta
-
hydroxy
-
estra
-
4,9,11
-
trien
-
17
-
one;
7
(28)
4
-
androstenediol;
8
(29)
4
-
androstenedione;
9
(30)
4
-
chloro
-
17alpha
-
methyl
-
androsta
-
1,4
-
diene
-
3,17beta
-
diol;
10
(31)
4
-
chloro
-
17alpha
-
methyl
-
androst
-
4
-
ene
-
3beta,17beta
-
diol;
1
1
(32)
4
-
chloro
-
17alpha
-
methyl
-
17beta
-
hydroxy
-
androst
-
4
-
en
-
3
-
one;
12
(33)
4
-
chloro
-
17alpha
-
methyl
-
17beta
-
hydroxy
-
androst
-
4
-
ene
-
3,11
-
13
dione;
14
(34)
4
-
hydroxy
-
19
-
nortestosterone;
15
(35)
4
-
hydroxy
-
androst
-
4
-
ene
-
3,17
-
dione;
16
(36)
4
-
hydroxytestosterone;
17
(37)
5alpha
-
androstan
-
3,17
-
dione;
18
(38)
5alpha
-
androstan
-
3,6,17
-
trione;
19
(39)
5
-
androstenediol;
20
(40)
5
-
androstenedione;
21
(41)
6alpha
-
methyl
-
androst
-
4
-
ene
-
3,17
-
dione;
22
(42)
6
-
bromo
-
androsta
-
1,4
-
diene
-
3,17
-
dione;
23
(43)
6
-
bromo
-
androstan
-
3,17
-
dione;
24
(44)
Androstenedione;
25
(45)
Bolasterone;
26
(46)
Boldenone;
27
(47)
Boldione;
28
(48)
Calusterone;
29
(49)
Chlorotestosterone
(4
-
chlorotestosterone);
30
(50)
Clostebol;
31
(51)
Dehydrochlormethyltestosterone;
32
(52)
Delta1
-
dihydrotestosterone
(1
-
testosterone)
;
33
(53)
Desoxymethyltestosterone
(madol)
;
34
(54)
Dihydrotestosterone
(4
-
dihydrotestosterone);
35
(55)
Drostanolone;
36
(56)
Estra
-
4,9,11
-
triene
-
3,17
-
dione;
37
(57)
Ethylestrenol;
38
(58)
Fluoxymesterone;
39
(59)
Formebulone
Formebolone
;
40
(60)
Furazabol;
41
(61)
Human
growth
hormones;
42
(62)
Mestanolone;
43
(63)
Mesterolone;
44
(64)
Methandienone;
45
(65)
Methandranone;
46
(66)
Methandriol;
47
(67)
Methandrostenolone;
48
(68)
Methasterone
(2a,
17a
-
dimethyl
-
5a
-
androstan
-
17β
-
ol
-
3
-
one)
;
49
(69)
Methenolone;
50

18
(70)
Methyldienolone;
1
(71)
Methyltestosterone;
2
(72)
Methyltrienolone;
3
(73)
Mibolerone;
4
(74)
Nandrolone;
5
(75)
Norbolethone;
6
(76)
Norclostebol;
7
(77)
Norethandrolone;
8
(78)
Normethandrolone;
9
(79)
Oxandrolone;
10
(80)
Oxymesterone;
1
1
(81)
Oxymetholone;
12
(82)
Prostanozol
(17β
-
hydroxy
-
5a
-
androstano[3,2
-
c]pyrazole)
;
13
(83)
Stanolone;
14
(84)
Stanozolol;
15
(85)
Stenbolone;
16
(86)
Testolactone;
17
(87)
Testosterone;
18
(88)
Testosterone
cypionate;
19
(89)
Testosterone
enanthate;
20
(90)
Testosterone
propionate;
21
(91)
Tetrahydrogestrinone;
22
(92)
Trenbolone.
23
Anabolic
steroids
that
are
expressly
intended
for
administration
24
through
implants
or
injection
to
cattle
or
other
nonhuman
species,
and
that
25
are
approved
by
the
federal
Food
and
Drug
Administration
for
such
use,
shall
26
not
be
classified
as
controlled
substances
under
this
act
and
shall
not
be
27
governed
by
its
provisions.
28
In
addition
to
the
penalties
prescribed
in
article
IV
of
the
uniform
29
controlled
substances
act,
any
person
shall
be
guilty
of
a
felony
who
pre
-
30
scribes,
dispenses,
supplies,
sells,
delivers,
manufactures
or
possesses
31
with
the
intent
to
prescribe,
dispense,
supply,
sell,
deliver
or
manufac
-
32
ture
anabolic
steroids
or
any
other
human
growth
hormone
for
purposes
of
33
enhancing
performance
in
an
exercise,
sport
or
game
or
hormonal
manipulation
34
intended
to
increase
muscle
mass,
strength
or
weight
without
a
medical
ne
-
35
cessity
as
determined
by
a
physician.
36
(g)
Hallucinogenic
substances.
37
(1)
Dronabinol
(synthetic)
in
sesame
oil
and
encapsulated
in
a
soft
38
gelatin
capsule
in
the
federal
Food
and
Drug
Administration
ap
-
39
proved
product
-
-
7369.
(Some
other
names
for
dronabinol:
(6aR
-
40
trans)
-
6a,7,8,10a
-
tetrahydro
-
6,6,9
-
trimethyl
-
3
-
pentyl
-
6H
-
dibenzo
41
[b,d]pyran
-
1
-
ol
or
(
-)
-
delta
-
9
-
(trans)
-
tetrahydrocannabinol)
.
42
(h)
The
board
may
except
by
rule
any
compound,
mixture,
or
preparation
43
containing
any
stimulant
or
depressant
substance
listed
in
subsection
(b)
44
or
(c)
of
this
section
from
the
application
of
all
or
any
part
of
this
act
if
45
the
compound,
mixture,
or
preparation
contains
one
(1)
or
more
active
medic
-
46
inal
ingredients
not
having
a
stimulant
or
depressant
effect
on
the
central
47
nervous
system,
and
if
the
admixtures
are
included
therein
in
combinations,
48
quantity,
proportion,
or
concentration
that
vitiate
the
potential
for
abuse
49

19
of
the
substances
which
have
a
stimulant
or
depressant
effect
on
the
central
1
nervous
system.
2
SECTION
4.
That
Section
37
-
2711,
Idaho
Code,
be,
and
the
same
is
hereby
3
amended
to
read
as
follows:
4
37
-
2711.
SCHEDULE
IV.
(a)
Schedule
IV
shall
consist
of
the
drugs
and
5
other
substances,
by
whatever
official
name,
common
or
usual
name,
chemical
6
name,
or
brand
name
designated,
listed
in
this
section.
7
(b)
Narcotic
drugs.
Unless
specifically
excepted
or
unless
listed
in
8
another
schedule,
any
material,
compound,
mixture,
or
preparation
contain
-
9
ing
any
of
the
following
narcotic
drugs,
or
their
salts
calculated
as
the
10
free
anhydrous
base
or
alkaloid,
in
limited
quantities
as
set
forth
below:
1
1
(1)
No
more
than
1
milligram
of
difenoxin
and
not
less
than
25
micro
-
12
grams
of
atropine
sulfate
per
dosage
unit;
13
(2)
Dextropropoxyphene
(alpha
-
(+)
-
4
-
dimethylamino
-
1,
2
-
diphenyl
-
14
3
-
methyl
-
2
-
propionoxybutane);
15
(3)
2
-
[(dimethylamino)methyl]
-
1
-
(3
-
methoxyphenyl)cyclohexanol
(in
-
16
cluding
tramadol)
Tramadol
,
including
its
salts,
optical
and
geometric
17
isomers,
and
salts
of
isomers.
18
(c)
Depressants.
Unless
specifically
excepted
or
unless
listed
in
an
-
19
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
20
tains
any
quantity
of
the
following
substances,
including
its
salts,
iso
-
21
mers,
and
salts
of
isomers
whenever
the
existence
of
such
salts,
isomers,
and
22
salts
of
isomers
is
possible
within
the
specific
chemical
designation:
23
(1)
Alfaxalone
5[alpha]
-
pregnan
-
3[alpha]
-
ol
-
11,20
-
dione;
24
(2)
Alprazolam;
25
(3)
Barbital;
26
(4)
Brexanolone
(allopregnanolone);
27
(4)
(5)
Bromazepam;
28
(5)
(6)
Camazepam;
29
(6)
(7)
Carisoprodol;
30
(7)
(8)
Chloral
betaine;
31
(8)
(9)
Chloral
hydrate;
32
(9)
(10)
Chlordiazepoxide;
33
(10)
(11)
Clobazam;
34
(11)
(12)
Clonazepam;
35
(12)
(13)
Clorazepate;
36
(13)
(14)
Clotiazepam;
37
(14)
(15)
Cloxazolam;
38
(15)
(16)
Daridorexant;
39
(16)
(17)
Delorazepam;
40
(17)
(18)
Diazepam;
41
(18)
(19)
Dichloralphenazone;
42
(19)
(20)
Estazolam;
43
(20)
(21)
Ethchlorvynol;
44
(21)
(22)
Ethinamate;
45
(22)
(23)
Ethyl
loflazepate;
46
(23)
(24)
Fludiazepam;
47
(24)
(25)
Flurazepam;
48
(25)
(26)
Fospropofol;
49

20
(26)
(27)
Halazepam;
1
(27)
(28)
Haloxazolam;
2
(28)
(29)
Ketazolam;
3
(29)
(30)
Lemborexant;
4
(30)
(31)
Loprazolam;
5
(31)
(32)
Lorazepam;
6
(32)
(33)
Lormetazepam;
7
(33)
(34)
Mebutamate;
8
(34)
(35)
Medazepam;
9
(35)
(36)
Meprobamate;
10
(36)
(37)
Methohexital;
1
1
(37)
(38)
Methylphenobarbital
(mephobarbital);
12
(38)
(39)
Midazolam;
13
(39)
(40)
Nimetazepam;
14
(40)
(41)
Nitrazepam;
15
(41)
(42)
Nordiazepam;
16
(42)
(43)
Oxazepam;
17
(43)
(44)
Oxazolam;
18
(44)
(45)
Paraldehyde;
19
(45)
(46)
Petrichloral;
20
(46)
(47)
Phenobarbital;
21
(47)
(48)
Pinazepam;
22
(48)
(49)
Prazepam;
23
(49)
(50)
Quazepam;
24
(50)
(51)
Remimazolam;
25
(51)
Serdexmethylpheniate;
26
(52)
Suvorexant;
27
(53)
Temazepam;
28
(54)
Tetrazepam;
29
(55)
Triazolam;
30
(56)
Zaleplon;
31
(57)
Zolpidem;
32
(58)
Zopiclone;
33
(59)
Zuranolone.
34
(d)
Fenfluramine
-
-
Any
material,
compound,
mixture,
or
preparation
35
which
contains
any
quantity
of
the
following
substances,
including
its
36
salts,
isomers
(whether
optical,
position,
or
geometric),
and
salts
of
such
37
isomers,
whenever
the
existence
of
such
salts,
isomers,
and
salts
of
isomers
38
is
possible:
39
(1)
Dexfenfluramine;
40
(2)
Fenfluramine.
41
(e)
Stimulants.
Unless
specifically
excepted
or
unless
listed
in
an
-
42
other
schedule,
any
material,
compound,
mixture,
or
preparation
which
con
-
43
tains
any
quantity
of
the
following
substances
having
a
stimulant
effect
on
44
the
central
nervous
system,
including
its
salts,
isomers
(whether
optical,
45
position,
or
geometric),
and
salts
of
such
isomers
whenever
the
existence
46
of
such
salts,
isomers,
and
salts
of
isomers
is
possible
within
the
specific
47
chemical
designation:
48
(1)
Cathine
((+)
-
norpseudoephedrine);
49
(2)
Diethylpropion;
50

21
(3)
Fencamfamin;
1
(4)
Fenproporex;
2
(5)
Lorcaserin;
3
(6)
Mazindol;
4
(7)
Mefenorex;
5
(8)
Modafinil;
6
(9)
Pemoline
(including
organometallic
complexes
and
chelates
7
thereof);
8
(10)
Phentermine;
9
(11)
Pipradrol;
10
(12)
Serdexmethylpheniate;
1
1
(12)
(13)
Sibutramine;
12
(13)
(14)
SPA
((
-)
-
1
-
dimethylamino
-
1,2
-
diphenylethane);
13
(14)
(15)
Solriamfetol
(2
-
amino
-
3
-
phenylpropyl
carbamata;
benzene
-
14
propanol,
beta
-
amino
-,
carbamate(ester))
.
15
(f)
Other
substances.
Unless
specifically
excepted,
or
unless
listed
16
in
another
schedule,
any
material,
compound,
mixture
or
preparation
which
17
contains
any
quantity
of
the
following
substances,
including
its
salts:
18
(1)
Brexanolone
(3A
-
hydroxy
-
5A
-
pregnan
-
20
-
one),
allopregnanolone;
19
(2)
(1)
Butorphanol
(including
its
optical
isomers);
20
(3)
(2)
Eluxadoline
(5
-
[[[(2S)
-
2
-
amino
-
3
-
[4
-
aminocarbonyl)
-
2,6
-
21
dimethylphenyl]
-
1
-
oxopropyl][(1S)
-
1
-
(4
-
phenyl
-
1H
-
imidazol
-
2
-
22
yl)ethyl]amino]methyl]
-
2
-
methoxybenzoic
acid)
(including
its
optical
23
isomers
)
and
its
salts,
isomers,
and
salts
of
isomers
)
;
24
(4)
(3)
Pentazocine.
25
(g)
The
board
may
except,
by
rule,
any
compound,
mixture,
or
prepara
-
26
tion
containing
any
depressant
substance
listed
in
subsection
(c)
of
this
27
section
from
the
application
of
all
or
any
part
of
this
act
if
the
compound,
28
mixture,
or
preparation
contains
one
(1)
or
more
active
medicinal
ingredi
-
29
ents
not
having
a
depressant
effect
on
the
central
nervous
system,
and
if
the
30
admixtures
are
included
therein
in
combinations,
quantity,
proportion,
or
31
concentration
that
vitiate
the
potential
for
abuse
of
the
substances
which
32
have
a
depressant
effect
on
the
central
nervous
system.
33
SECTION
5.
That
Section
37
-
2713,
Idaho
Code,
be,
and
the
same
is
hereby
34
amended
to
read
as
follows:
35
37
-
2713.
SCHEDULE
V.
(a)
Schedule
V
shall
consist
of
the
drugs
and
36
other
substances,
by
whatever
official
name,
common
or
usual
name,
chemical
37
name,
or
brand
name
designated,
listed
in
this
section.
38
(b)
Narcotic
drugs.
Unless
specifically
excepted
or
unless
listed
in
39
another
schedule,
any
material,
compound,
mixture,
or
preparation
contain
-
40
ing
any
of
the
following
narcotic
drugs
and
their
salts,
as
set
forth
below.
41
(c)
Narcotic
drugs
containing
nonnarcotic
active
medicinal
ingredi
-
42
ents.
Any
compound,
mixture,
or
preparation
containing
any
of
the
follow
-
43
ing
limited
quantities
of
narcotic
drugs
or
salts
thereof,
which
shall
in
-
44
clude
one
(1)
or
more
nonnarcotic
active
medicinal
ingredients
in
sufficient
45
proportion
to
confer
upon
the
compound,
mixture,
or
preparation,
valuable
46
medicinal
qualities
other
than
those
possessed
by
the
narcotic
drug
alone:
47
(1)
Not
more
than
200
milligrams
of
codeine
per
100
milliliters
or
per
48
100
grams;
49

22
(2)
Not
more
than
100
milligrams
of
dihydrocodeine
per
100
milliliters
1
or
per
100
grams;
2
(3)
Not
more
than
100
milligrams
of
ethylmorphine
per
100
milliliters
3
or
per
100
grams;
4
(4)
Not
more
than
2.5
milligrams
of
diphenoxylate
and
not
less
than
25
5
micrograms
of
atropine
sulfate
per
dosage
unit;
6
(5)
Not
more
than
100
milligrams
of
opium
per
100
milliliters
or
per
100
7
grams;
8
(6)
Not
more
than
0.5
milligrams
difenoxin
and
not
less
than
25
micro
-
9
grams
of
atropine
sulfate
per
dosage
unit.
10
(d)
Other
substances.
Unless
specifically
excepted
or
unless
listed
1
1
in
another
schedule,
any
material,
compound,
mixture
or
preparation
which
12
contains
any
quantity
of
the
following
substances,
including
its
salts:
13
(1)
Brivaracetam
(
(2S)
-
2
-
[(4R)
-
2
-
oxo
-
4
-
propylpyrrolidin
-
1
-
yl]bu
-
14
tanamide)
(also
referred
to
as
BRV;
UCB
-
34714;
Briviact)
(including
its
15
salts);
16
(2)
Cenobamate
[(1R)
-
1
-
(2
-
chlorophenyl)
-
2
-
(tetrazol
-
2
-
yl)ethyl]car
-
17
bamate
;
18
(3)
Ezogabine
[N
-
[2
-
amino
-
4
-
(4
-
fluorobenzylamino)
-
phenyl]
-
carbamic
19
acid
ethyl
ester]
-
2779
;
20
(4)
Ganaxolone
(3
-
alpha
-
hydroxy
-
3
-
beta
-
methyl
-
5
-
alpha
-
preg
-
21
nan
-
20
-
one)
;
22
(5)
Lacosamide;
23
(6)
Lasmiditan
[2,4,6
-
trifluoro
-
N
-
(6
-
(1
-
methylpiperidine
-
4
-
car
-
24
bonyl)pyridine
-
2
-
yl)benzamide]
;
25
(7)
Pregabalin;
26
(8)
Pyrovalerone.
27
SECTION
6.
That
Section
37
-
2716,
Idaho
Code,
be,
and
the
same
is
hereby
28
amended
to
read
as
follows:
29
37
-
2716.
REGISTRATION
REQUIREMENTS.
(a)
Every
person
who
manufac
-
30
tures,
distributes,
prescribes,
administers,
or
conducts
research
with
any
31
controlled
substance
within
this
state
shall
obtain
annually
biennially
a
32
registration
issued
by
the
board
in
accordance
with
Idaho
law.
All
drug
out
-
33
lets
with
a
valid
license
or
registration
under
chapter
17,
title
54,
Idaho
34
Code,
are
exempt
from
obtaining
a
separate
controlled
substance
registra
-
35
tion.
36
(b)
Every
dispenser
and
prescriber,
except
veterinarians,
shall
also
37
register
with
the
division
to
obtain
online
access
to
the
controlled
sub
-
38
stances
prescriptions
database.
39
(c)
Persons
registered
by
the
board
under
this
chapter
may
possess,
40
manufacture,
distribute,
dispense,
prescribe,
administer,
or
conduct
re
-
41
search
with
those
substances
to
the
extent
authorized
by
their
registration
42
and
licensing
entity
and
in
conformity
with
the
other
provisions
of
this
43
chapter.
44
(d)
The
following
persons
need
not
register
and
may
lawfully
possess
45
controlled
substances
under
this
chapter:
46
(1)
An
agent
or
employee
of
any
person
registered
pursuant
to
this
chap
-
47
ter,
if
he
is
acting
in
the
usual
course
of
his
business
or
employment;
48

23
(2)
A
common
or
contract
carrier
or
warehouseman,
or
an
employee
1
thereof,
whose
possession
of
any
controlled
substance
is
in
the
usual
2
course
of
business
or
employment;
3
(3)
An
ultimate
user
or
a
person
in
possession
of
any
controlled
sub
-
4
stance
pursuant
to
a
lawful
order
of
a
practitioner
or
in
lawful
posses
-
5
sion
of
a
schedule
V
substance.
6
(e)
A
separate
registration
is
required
at
each
principal
place
of
7
business
or
professional
practice
where
the
applicant
manufactures,
dis
-
8
tributes,
administers,
dispenses,
or
conducts
research
with
controlled
9
substances,
except
a
separate
registration
is
not
required
under
this
chap
-
10
ter
for
practitioners
engaging
in
research
with
nonnarcotic
controlled
1
1
substances
in
schedules
II
through
IV
where
the
practitioner
is
already
reg
-
12
istered
under
this
chapter
in
another
capacity.
13
(f)
Practitioners
registered
under
federal
law
to
conduct
research
14
with
schedule
I
substances
may
conduct
research
with
schedule
I
substances
15
within
this
state
upon
registering
in
Idaho
and
furnishing
the
board
with
16
evidence
of
the
practitioner's
federal
registration.
17
(g)
The
board
may
inspect
the
establishment
of
a
registrant
or
appli
-
18
cant
for
registration
in
accordance
with
Idaho
law.
19
SECTION
7.
That
Section
37
-
2717,
Idaho
Code,
be,
and
the
same
is
hereby
20
amended
to
read
as
follows:
21
37
-
2717.
REGISTRATION.
The
board
shall
register
an
applicant
to
man
-
22
ufacture,
prescribe,
administer,
dispense,
distribute
or
conduct
research
23
with
controlled
substances
included
in
sections
37
-
2705,
37
-
2707,
37
-
2709,
24
37
-
2711
and
37
-
2713,
Idaho
Code,
unless
it
determines
that
the
issuance
of
25
that
registration
would
be
inconsistent
with
the
public
interest.
In
deter
-
26
mining
the
public
interest,
the
board
shall
consider
the
following
factors:
27
(a)
Maintenance
of
effective
controls
against
diversion
of
controlled
28
substances
into
other
than
legitimate
medical,
scientific,
or
industrial
29
channels;
30
(b)
Compliance
with
applicable
state
and
local
law;
31
(c)
Any
convictions
of
the
applicant
under
any
federal
and
state
laws
32
relating
to
any
controlled
substance;
33
(d)
Past
experience
Experience
in
the
manufacture,
dispensing,
34
prescribing,
administering,
research
or
distribution
of
controlled
sub
-
35
stances,
and
the
existence
in
the
applicant's
establishment
of
effective
36
controls
against
diversions;
37
(e)
Furnishing
by
the
applicant
of
false
or
fraudulent
material
in
any
38
application
filed
under
this
chapter;
39
(f)
Restriction,
suspension
or
revocation
of
the
applicant's
federal
40
registration;
and
41
(g)
Any
other
factors
relevant
to
and
consistent
with
the
public
health
42
and
safety.
43
SECTION
8.
That
Section
37
-
2718,
Idaho
Code,
be,
and
the
same
is
hereby
44
amended
to
read
as
follows:
45

24
37
-
2718.
DISCIPLINE.
(a)
A
registration
under
section
37
-
2717,
Idaho
1
Code,
may
be
restricted,
suspended
or
revoked
by
the
board
upon
a
finding
2
that
the
registrant:
3
(1)
Has
furnished
false
or
fraudulent
material
information
in
any
ap
-
4
plication
filed
under
this
act;
5
(2)
Has
been
found
guilty
of
a
felony
or
misdemeanor
under
any
state
or
6
federal
law
relating
to
any
controlled
substance;
7
(3)
Has
had
his
federal
registration
restricted,
suspended
or
revoked;
8
or
9
(4)
Has
violated
this
chapter,
any
rule
of
the
board
promulgated
un
-
10
der
this
act,
an
order
of
the
board
or
any
federal
regulation
relating
to
1
1
controlled
substances;
provided,
however,
that
no
restriction,
revoca
-
12
tion
or
suspension
procedure
be
initiated
under
this
paragraph
without
13
the
board
first
giving
notice
of
the
procedure
to
the
state
licensing
14
board
with
authority
over
the
registrant's
professional
license.
15
(b)
The
notice
required
in
subsection
(a)(4)
of
this
section
shall
be
16
given
immediately
in
the
event
action
is
taken
without
an
order
to
show
cause
17
as
allowed
under
section
37
-
2719(b),
Idaho
Code.
In
all
other
cases,
such
18
notice
shall
be
given
as
early
as
reasonably
practicable
without
risking
19
compromise
of
the
board's
investigation
but
no
later
than
the
earlier
of:
20
(1)
Issuance
of
an
order
to
show
cause
under
section
37
-
2719(a),
Idaho
21
Code;
or
22
(2)
Setting
of
a
hearing
for
approval
of
a
resolution
of
the
matter
23
through
informal
proceedings.
24
(c)
Restriction,
revocation
or
suspension
procedures
arising
solely
25
from
"practice
-
related
issues"
shall
be
referred
by
the
board
to
such
regis
-
26
trant's
state
licensing
board.
27
(1)
Upon
such
referral,
the
registrant's
state
licensing
board
shall
28
commence
such
investigation
of
the
referred
matter
as
it
deems
neces
-
29
sary
and
shall
take
action
upon
the
registrant's
license
or
shall
inform
30
the
board
of
pharmacy,
in
writing,
that
it
has
investigated
the
referred
31
matter
and
has
concluded
that
no
action
is
necessary.
32
(2)
For
purposes
of
this
section,
the
term
"practice
-
related
issues"
33
refers
to
issues
involving
questions
regarding
the
professional
con
-
34
duct
of
the
registrant
within
the
scope
of
the
registrant's
profession.
35
(d)
The
board
may
limit
the
revocation
or
suspension
of
a
registration
36
to
the
particular
controlled
substance
with
respect
to
which
grounds
for
re
-
37
vocation
or
suspension
exist.
38
(e)
If
the
board
restricts,
suspends
or
revokes
a
registration,
all
39
pertinent
controlled
substances
owned
or
possessed
by
the
registrant
at
the
40
time
of
the
restriction
or
suspension
or
the
effective
date
of
the
revocation
41
order
may
shall
be
placed
under
seal.
No
disposition
may
be
made
of
sub
-
42
stances
under
seal
until
the
time
for
taking
an
appeal
has
elapsed
or
until
43
all
appeals
have
been
concluded
unless
a
court,
upon
application
therefor,
44
orders
the
sale
of
perishable
substances
and
the
deposit
of
the
proceeds
of
45
the
sale
with
the
court.
Upon
a
revocation
order
becoming
final,
all
con
-
46
trolled
substances
may
be
forfeited
to
the
state
for
transfer
to
a
reverse
47
distributor
.
48
(f)
The
board
shall
promptly
notify
the
bureau
and
the
state
licensing
49
board
with
authority
over
the
registrant's
professional
license
of
all
or
-
50

25
ders
restricting,
suspending
or
revoking
registration
and
all
forfeitures
1
of
controlled
substances.
2
(g)
In
the
event
the
drug
enforcement
administration
or
a
state
li
-
3
censing
board
with
authority
over
a
registrant's
professional
license
or
4
registration
takes
an
action
against
the
registrant
in
any
fashion
which
5
suspends,
restricts,
limits
or
affects
the
registrant's
ability
to
manufac
-
6
ture,
distribute,
prescribe,
administer,
dispense,
or
conduct
research
with
7
any
controlled
substance,
the
professional
licensing
board
shall
promptly
8
notify
the
board
of
pharmacy
of
the
action.
9
(1)
Upon
such
action,
the
board
of
pharmacy
shall
be
authorized
to
issue
10
its
order
suspending,
restricting,
limiting
or
otherwise
affecting
the
1
1
registrant's
controlled
substance
registration
in
the
same
fashion
as
12
the
professional
licensing
board
action.
13
(2)
The
board
of
pharmacy
order
may
be
issued
without
further
hearing
or
14
proceeding,
but
shall
be
subject
to
the
effect
of
any
reversal
or
modi
-
15
fication
of
the
professional
licensing
board
action
by
reason
of
any
ap
-
16
peal
or
rehearing.
17
SECTION
9.
That
Section
37
-
2719,
Idaho
Code,
be,
and
the
same
is
hereby
18
amended
to
read
as
follows:
19
37
-
2719.
ORDER
TO
SHOW
CAUSE.
(a)
Except
as
set
forth
in
section
20
37
-
2718(g),
Idaho
Code,
before
denying,
restricting,
suspending
or
revoking
21
a
registration,
or
refusing
a
renewal
of
registration,
the
board
shall
serve
22
upon
the
applicant
or
registrant
an
order
to
show
cause
why
the
registration
23
should
not
be
restricted,
denied,
revoked,
or
suspended,
or
why
the
renewal
24
should
not
be
refused.
The
order
to
show
cause
shall
contain
a
statement
25
of
the
basis
therefor
for
discipline
and
shall
call
upon
the
applicant
or
26
registrant
to
appear
before
the
board
at
a
time
and
place
not
less
than
thirty
27
(30)
days
after
the
date
of
service
of
the
order,
but
in
the
case
of
a
an
28
anticipated
denial
or
of
renewal
of
registration
the
show
cause
order
shall
29
be
served
not
later
than
thirty
(30)
days
before
the
expiration
of
the
reg
-
30
istration.
These
proceedings
shall
be
conducted
in
accordance
with
chapter
31
52,
title
67,
Idaho
Code,
without
regard
to
any
criminal
prosecution
or
other
32
proceeding.
Proceedings
to
refuse
renewal
of
registration
shall
not
abate
33
the
existing
registration
which
shall
remain
in
effect
pending
the
outcome
34
of
the
administrative
hearing.
35
(b)
The
board
may
suspend,
without
an
order
to
show
cause,
any
regis
-
36
tration
simultaneously
with
the
institution
of
proceedings
under
section
37
37
-
2718,
Idaho
Code,
or
where
renewal
of
registration
is
refused,
if
it
finds
38
that
there
is
an
imminent
danger
to
the
public
health
or
safety
which
war
-
39
rants
this
action.
The
suspension
shall
continue
in
effect
until
the
conclu
-
40
sion
of
the
proceedings,
including
judicial
review
thereof,
unless
sooner
41
withdrawn
by
the
board
or
dissolved
by
a
court
of
competent
jurisdiction.
42
(c)
In
conjunction
with
a
proceeding
for
denying,
restricting,
sus
-
43
pending
or
revoking
a
registration,
or
refusing
a
renewal
of
registration,
44
and
upon
a
finding
of
grounds
for
such
denial,
restriction,
suspension,
45
revocation
or
refusal
to
renew,
the
board
may
also
impose
an
a
reasonable
ad
-
46
ministrative
fine
not
to
exceed
two
thousand
dollars
($2,000)
per
occurrence
47
and
additionally
may
include
forfeiture
of
illicit
profits
and
the
costs
of
48

26
prosecution
and
administrative
costs
of
bringing
the
action
including,
but
1
not
limited
to,
attorney's
fees
and
costs
and
costs
of
hearing
transcripts.
2
SECTION
10.
That
Section
37
-
2720,
Idaho
Code,
be,
and
the
same
is
hereby
3
amended
to
read
as
follows:
4
37
-
2720.
RECORDS
-
-
DRUG
STORAGE
-
-
INVENTORY.
Persons
registered
un
-
5
der
this
chapter
shall
keep
records,
store
controlled
substances
and
main
-
6
tain
inventories
in
conformance
with
the
recordkeeping,
storage
and
inven
-
7
tory
requirements
of
state
and
federal
law
and
with
any
additional
rules
the
8
board
issues
.
9
SECTION
11.
That
Section
37
-
2722,
Idaho
Code,
be,
and
the
same
is
hereby
10
amended
to
read
as
follows:
1
1
37
-
2722.
ISSUING,
DISTRIBUTING,
AND
DISPENSING
OF
CONTROLLED
SUB
-
12
STANCES.
No
person
shall
issue
or
dispense
a
prescription
drug
order
for
a
13
controlled
substance
unless
it
is
in
compliance
with
applicable
state
and
14
federal
law
and
rules
of
the
board
.
15
(a)
Controlled
substances
included
in
schedule
I
shall
be
distributed
16
only
by
a
registrant
to
another
registrant
pursuant
to
the
federal
drug
en
-
17
forcement
administration
(DEA)
order
form
222.
18
(b)
Controlled
substances
included
in
schedule
II
shall:
19
(1)
Be
distributed
only
by
a
registrant
to
another
registrant
pursuant
20
to
DEA
order
form
222.
21
(2)
Be
dispensed
only
pursuant
to
a
valid
prescription
drug
order,
ex
-
22
cept
when
dispensed
directly
by
a
prescriber.
23
(3)
Not
be
refilled.
24
(4)
Include
a
quantity
that
is
both
spelled
out
in
English
and
written
25
in
numerical
form,
when
a
written
prescription
drug
order
is
required.
26
(c)
Controlled
substances
included
in
schedule
III
or
IV
shall:
27
(1)
Be
dispensed
only
pursuant
to
a
valid
prescription
drug
order,
ex
-
28
cept
when
dispensed
directly
by
a
prescriber.
29
(2)
Not
be
filled
or
refilled
more
than
six
(6)
months
after
the
date
30
thereof
or
be
refilled
more
than
five
(5)
times,
unless
renewed
by
the
31
practitioner.
32
(d)
Controlled
substances
included
in
schedule
V
shall
not
be
dis
-
33
tributed
or
dispensed
other
than
for
a
medical
purpose.
34
(e)
A
pharmacist
may
dispense
a
controlled
substance
pursuant
to
a
35
valid
prescription
drug
order
of
an
individual
licensed
in
a
jurisdiction
36
other
than
the
state
of
Idaho
as
long
as
the
individual
is
acting
within
the
37
jurisdiction,
scope
and
authority
of
his
license.
38
(f)
Prior
to
issuing
to
a
patient
a
prescription
for
outpatient
use
39
for
an
opioid
analgesic
or
benzodiazepine
listed
in
schedule
II,
III,
or
40
IV,
the
prescriber
or
the
prescriber's
delegate
shall
review
the
patient's
41
prescription
drug
history
for
the
preceding
twelve
(12)
months
from
the
pre
-
42
scription
drug
monitoring
program
and
evaluate
the
data
for
indicators
of
43
prescription
drug
diversion
or
misuse.
This
review
is
not
required:
44
(1)
For
patients:
45
(i)
i.
Receiving
treatment
in
an
inpatient
setting;
46
(ii)
ii.
At
the
scene
of
an
emergency
or
in
an
ambulance;
47

27
(iii)
iii.
In
hospice
care;
or
1
(iv)
iv.
In
a
skilled
nursing
home
care
facility;
or
2
(2)
For
a
prescription
in
a
quantity
intended
to
last
no
more
than
three
3
(3)
days.
4
(g)
Subsection
(f)
of
this
section
shall
be
effective
on
and
after
Octo
-
5
ber
1,
2020,
and
shall
apply
only
to
individuals
required
by
this
chapter
to
6
register
for
the
prescription
drug
monitoring
program.
7
SECTION
12.
That
Section
37
-
2726,
Idaho
Code,
be,
and
the
same
is
hereby
8
amended
to
read
as
follows:
9
37
-
2726.
FILING
PRESCRIPTIONS
-
-
DATABASE.
(1)
All
controlled
sub
-
10
stances
and
opioid
antagonists
as
defined
in
section
54
-
1704,
Idaho
Code,
1
1
dispensed
for
humans
shall
be
filed
with
the
division
electronically
in
a
12
format
established
by
the
division.
The
division
may
require
the
filing
of
13
other
prescriptions
by
law
or
rule.
The
division
shall
establish
the
in
-
14
formation
to
be
submitted
pursuant
to
the
purposes
of
this
section
and
the
15
purposes
set
forth
in
section
37
-
2730A,
Idaho
Code.
16
(2)
The
division
shall
create,
operate
and
maintain
a
controlled
17
substances
prescriptions
database
containing
the
information
submitted
18
pursuant
to
subsection
(1)
of
this
section
to
be
used
for
the
purposes
19
and
subject
to
the
terms,
conditions
and
immunities
described
in
section
20
37
-
2730A,
Idaho
Code.
The
division
shall
retain
the
information
submitted
21
pursuant
to
subsection
(1)
of
this
section
for
a
period
of
five
(5)
years
from
22
the
date
the
controlled
substance
was
dispensed.
The
database
information
23
must
may
be
made
available
only
to
the
following:
24
(a)
Authorized
individuals
employed
by
the
division,
Idaho's
boards,
25
or
other
states'
licensing
entities
charged
with
the
licensing
and
dis
-
26
cipline
of
practitioners;
27
(b)
Peace
officers
and
investigators
employed
by
federal,
state
and
lo
-
28
cal
law
enforcement
agencies
engaged
as
a
specified
duty
of
their
em
-
29
ployment
in
enforcing
law
regulating
controlled
substances;
30
(c)
Authorized
individuals
under
the
direction
of
the
department
of
31
health
and
welfare
for
the
purpose
of
monitoring
and
enforcing
that
32
department's
responsibilities
under
the
public
health,
medicare
and
33
medicaid
laws;
34
(d)
A
practitioner,
licensed
in
Idaho
or
another
state,
having
author
-
35
ity
to
prescribe
controlled
substances,
or
a
delegate
under
the
prac
-
36
titioner's
supervision,
to
the
extent
the
information
relates
specifi
-
37
cally
to
a
current
patient
of
the
practitioner
to
whom
the
practitioner
38
is
prescribing
or
considering
prescribing
any
controlled
substance;
39
(e)
A
pharmacist,
licensed
in
Idaho
or
another
state,
having
author
-
40
ity
to
dispense
controlled
substances,
or
a
delegate
under
the
pharma
-
41
cist's
supervision,
to
the
extent
the
information
relates
specifically
42
to
a
current
patient
to
whom
that
pharmacist
is
dispensing
or
consid
-
43
ering
dispensing
any
controlled
substance,
or
providing
pharmaceutical
44
care
as
defined
in
the
Idaho
pharmacy
act;
45
(f)
An
individual
who
is
the
recipient
of
a
dispensed
controlled
sub
-
46
stance
entered
into
the
database
may
access
records
that
pertain
to
that
47
individual,
upon
the
production
of
positive
identification,
or
that
in
-
48
dividual's
designee
upon
production
of
a
notarized
release
of
informa
-
49

28
tion
by
that
individual
that
is
notarized
or
otherwise
certified
pur
-
1
suant
to
section
9
-
1406,
Idaho
Code
;
2
(g)
Upon
a
lawful
order
issued
by
the
presiding
judge
in
a
court
of
com
-
3
petent
jurisdiction
for
the
release
of
prescription
monitoring
program
4
records
of
a
named
individual;
5
(h)
Prosecuting
attorneys,
deputy
prosecuting
attorneys
,
and
special
6
prosecutors
of
a
county
or
city
employed
by
federal,
state,
county,
or
7
local
agencies
and
special
assistant
attorneys
general
from
the
office
8
of
the
attorney
general
engaged
in
enforcing
law
regulating
controlled
9
substances;
and
10
(i)
A
medical
examiner
or
coroner
who
is
an
officer
of
or
employed
by
a
1
1
state
or
local
government,
for
determining
a
cause
of
death
or
for
per
-
12
forming
other
duties
authorized
by
law.
13
(3)
The
division
shall
require
pharmacists
and
prescribers,
except
14
veterinarians,
to
register
with
the
division
to
obtain
online
access
to
the
15
controlled
substances
prescriptions
database.
16
(4)
(3)
The
division
must
maintain
records
on
the
information
disclosed
17
from
the
database,
including:
18
(a)
The
identification
of
each
individual
who
requests
or
receives
in
-
19
formation
from
the
database
and
who
that
individual
represents;
20
(b)
The
information
provided
to
each
such
individual;
and
21
(c)
The
date
and
time
the
information
is
requested
or
provided.
22
(5)
(4)
The
division
shall
ensure
that
only
authorized
individuals
have
23
access
to
the
database.
24
(6)
(5)(a)
Any
person
who
knowingly
misrepresents
to
the
division
that
25
he
is
a
person
entitled
under
subsection
(2)
of
this
section
to
receive
26
information
from
the
controlled
substances
prescriptions
database
un
-
27
der
the
conditions
therein
provided,
and
who
receives
information
from
28
the
controlled
substances
prescriptions
database
resulting
from
that
29
misrepresentation,
A
person
is
guilty
of
a
misdemeanor
if
such
person:
30
(i)
Knowingly
misrepresents
to
the
division
that
he
is
a
person
31
entitled
to
receive
information
from
the
controlled
substances
32
prescriptions
database
pursuant
to
subsection
(2)
of
this
section
33
and
receives
information
from
the
controlled
substances
prescrip
-
34
tions
database
as
a
result
of
such
misrepresentation;
35
(ii)
Knowingly
discloses
information
obtained
from
the
con
-
36
trolled
substances
prescriptions
database
that
identifies
an
in
-
37
dividual
patient
to
a
person
not
authorized
to
receive
or
use
such
38
information
under
any
state
or
federal
law,
rule,
or
regulation,
39
without
the
lawful
order
of
a
court
of
competent
jurisdiction,
or
40
without
written
authorization.
The
provisions
of
this
subpara
-
41
graph
shall
not
apply
to
disclosure
of
individual
patient
infor
-
42
mation
by
the
patient
himself
or
disclosure
of
individual
patient
43
information
by
a
federal,
state,
or
local
prosecuting
attorney,
44
a
deputy
prosecuting
attorney
or
special
prosecutor,
or
a
special
45
assistant
attorney
general
from
the
office
of
the
attorney
general
46
in
the
course
of
a
criminal
proceeding,
whether
preconviction
or
47
post
-
conviction;
or
48
(iii)
Intentionally
shares
or
recklessly
fails
to
safeguard
a
49
division
-
issued
user
account,
login
name,
or
password,
result
-
50

29
ing
in
another
person
obtaining
information
from
the
controlled
1
substances
prescriptions
database
when
such
other
person
is
not
2
authorized
to
receive
or
use
such
information
under
the
provisions
3
of
any
state
or
federal
law,
rule,
or
regulation.
4
(b)
Any
person
who
violates
the
provisions
of
paragraph
(a)
of
this
sub
-
5
section
shall
be
guilty
of
a
misdemeanor,
punishable
by
imprisonment
in
6
a
county
jail
not
to
exceed
six
(6)
months,
or
by
a
fine
not
to
exceed
7
two
thousand
dollars
($2,000),
or
both.
The
foregoing
criminal
penalty
8
is
in
addition
to,
and
not
in
lieu
of,
any
other
civil
or
administrative
9
penalty
or
sanction
authorized
by
law.
10
(7)
Any
person
in
possession,
whether
lawfully
or
unlawfully,
of
infor
-
1
1
mation
from
the
controlled
substances
prescriptions
database
that
identi
-
12
fies
an
individual
patient
and
who
knowingly
discloses
such
information
to
a
13
person
not
authorized
to
receive
or
use
such
information
under
any
state
or
14
federal
law
or
rule
or
regulation,
or
the
lawful
order
of
a
court
of
competent
15
jurisdiction,
or
without
written
authorization
of
the
individual
patient
16
shall
be
guilty
of
a
misdemeanor,
punishable
by
imprisonment
in
a
county
jail
17
not
to
exceed
six
(6)
months,
or
by
a
fine
not
to
exceed
two
thousand
dollars
18
($2,000),
or
both.
The
foregoing
criminal
penalty
is
in
addition
to,
and
not
19
in
lieu
of,
any
other
civil
or
administrative
penalty
or
sanction
authorized
20
by
law.
The
provisions
of
this
subsection
shall
not
apply
to
disclosure
of
21
individual
patient
information
by
the
patient
himself.
The
provisions
of
22
this
subsection
shall
not
apply
to
disclosure
of
information
by
a
prosecut
-
23
ing
attorney,
deputy
prosecuting
attorney
or
special
prosecutor
of
a
county
24
or
city
or
by
a
special
assistant
attorney
general
from
the
office
of
the
at
-
25
torney
general
in
the
course
of
a
criminal
proceeding,
whether
preconviction
26
or
postconviction.
27
(8)
Any
person
with
access
to
the
division's
online
prescription
mon
-
28
itoring
program
pursuant
to
a
division
-
issued
user
account,
login
name
and
29
password
who
intentionally
shares
or
recklessly
fails
to
safeguard
his
user
30
account,
login
name
and
password,
resulting
in
another
person
not
authorized
31
to
receive
or
use
such
information
under
the
provisions
of
any
state
or
fed
-
32
eral
law,
rule
or
regulation
obtaining
information
from
the
controlled
sub
-
33
stances
prescriptions
database,
shall
be
guilty
of
a
misdemeanor,
punish
-
34
able
by
imprisonment
in
a
county
jail
not
to
exceed
six
(6)
months
or
by
a
fine
35
not
to
exceed
two
thousand
dollars
($2,000),
or
both.
The
foregoing
criminal
36
penalty
is
in
addition
to,
and
not
in
lieu
of,
any
other
civil
or
administra
-
37
tive
penalty
or
sanction
authorized
by
law.
38
(9)
(6)
The
division
may,
at
its
discretion,
block
access
to
certain
39
controlled
substances
prescriptions
database
data
if
the
division
has
rea
-
40
son
to
believe
that
access
to
the
data
is
or
may
be
used
illegally.
41
(10)
(7)
All
costs
associated
with
recording
and
submitting
data
as
re
-
42
quired
in
this
section
are
assumed
by
the
dispensing
practitioner
recording
43
and
submitting
the
data.
44
(11)
(8)
For
purposes
of
this
section,
"delegate"
means
a
nurse,
medi
-
45
cal
or
office
assistant,
current
student
of
a
health
profession
if
the
health
46
care
staff,
current
health
profession
student
of
a
licensed
practitioner
or
47
registered
graduate
of
such
profession
who
may
access
the
database,
or
a
reg
-
48
istered
pharmacy
technician
who
is
designated
by
a
supervising
practitioner
49

30
or
pharmacist
to
access
the
database
according
to
the
provisions
of
this
sec
-
1
tion
and
who
must
register
with
the
division
for
such
access.
2
SECTION
13.
That
Section
37
-
2731,
Idaho
Code,
be,
and
the
same
is
hereby
3
amended
to
read
as
follows:
4
37
-
2731.
INFORMATION
REQUIRED
ON
LABEL.
A
practitioner
with
statutory
5
authority
to
dispense
a
controlled
substance
shall
affix
to
the
package
a
la
-
6
bel
pursuant
to
board
rule
Idaho
law
.
7
SECTION
14.
An
emergency
existing
therefor,
which
emergency
is
hereby
8
declared
to
exist,
this
act
shall
be
in
full
force
and
effect
on
and
after
9
July
1,
2026.
10